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Summary  
Buruli ulcer (BU) is a necrotizing skin disease caused by Mycobacterium ulcerans which, if 
untreated, can lead to extensive tissue destruction and ulceration. The disease has been 
reported from over 30 countries with the highest prevalence in West Africa. Generally it is 
assumed that M. ulcerans is acquired from environmental sources, but BU is considered a 
“mysterious disease” because the natural reservoir and the mode of transmission are still not 
identified. Clinically BU presents with a spectrum of forms ranging from non-ulcerative 
lesions to large ulcers. The gold standard for diagnosing BU is IS2404 qPCR, which is a 
sophisticated technology not applicable in the field, where BU is often diagnosed on the basis 
of clinical signs and symptoms only. Direct microscopic smear examination after Ziehl-
Neelsen staining, which has a low sensitivity, is the only point-of-care laboratory diagnostic 
method currently available. Since 2004, the WHO recommends to treat BU with a 
combination of streptomycin and rifampicin daily for 8 weeks. While this specific treatment is 
highly effective in killing the bacteria, healing of large ulcers may require long periods of 
time.  
The Bankim Health District (HD) in the Mapé dam basin of Cameroon has been recently 
identified as BU endemic area and a new BU field research site was established by us in 2010. 
Within the framework of this thesis, we have contributed to strengthening of the local BU 
treatment and research site by the implementation of a surveillance and documentation system 
to promote a continuous case detection and follow up of patients, to investigate the pathway 
of transmission and to perform a comprehensive spatio-temporal distribution analysis of BU 
in the area.  
Local clinical and microscopic diagnosis was re-confirmed by qPCR, bacterial culture and 
histopathology performed in Basel. The in-depth analysis on 148 qPCR confirmed cases 
underlined that BU is a pediatric disease in Africa and that the lesions occur mainly at the 
limbs with no differences amongst males and females. We obtained information on the exact 
geographical origin of 136 qPCR positive BU patients through mapping of their houses and 
farms. Results revealed for the majority of patients residence or agricultural activities close to 
the Mbam river. Sites of environmental contact of BU patients were screened to search for 
potential reservoirs of M. ulcerans. At one village water site, DNA of M. ulcerans, was 
persistently found over more than 2 years, indicating that the pathogen may persist in detritus.  
Because some of the BU lesions healed very fast, while others showed an impaired healing 
process, we analyzed tissue samples in detail for the presence of wound healing and scarring 
Summary 
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biomarkers. Using the histopathological approach, we evaluated the use of markers of cell 
activation, myofibroblast formation and matrix deposition for the monitoring of the healing of 
BU lesions. While α-smooth muscle actin-positive myofibroblasts were not found in untreated 
lesions, they emerged during the healing process. These cells produced abundant extracellular 
matrix proteins, such as procollagen 1 and tenascin and were found in fibronectin rich areas. 
After antibiotic treatment many cells, including myofibroblasts, revealed an activated 
phenotype. Healing wounds showed dermal tissue remodelling by apoptosis, and increased 
cytokeratin 16 expression in the epidermis.  
 
Taken together, the results described in this thesis were obtained by a multidisciplinary 
approach. They contribute to our understanding of BU epidemiology and transmission, as 
well as of pathogenesis, wound healing and may eventually help to improve diagnosis, 
treatment and prevention of BU.  
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Buruli ulcer (BU) is a neglected tropical disease (NTD) caused by Mycobacterium ulcerans, 
the third most common mycobacterial infection after tuberculosis and leprosy. It is worldwide 
present but largely a problem of poor tropical West African countries causing a lot of human 
suffering. Major efforts and measures to control the disease were initiated by the World 
Health Organization (WHO) in 1998 with the “Yamoussoukro Declaration on Buruli Ulcer”. 
Over the last 20 years these measures, together with interventions tackling other NTDs, were 
enhanced and implemented with the objective to intensify research, diagnosis, treatment, 
management and prevention to control these diseases and to reduce their burden [1]. 
 
 
1.1. History and Epidemiology 
BU disease was first discovered by Sir Albert Cook in 1987 in Uganda but the definitive 
characterization and the isolation of the agent responsible for the disease, occurred only in 
1948 by MacCallum, an Australian bacteriologist. He published an article titled “A new 
mycobacterial infection in man” in which he described 6 Australian cases reporting an 
unusual skin ulceration with undermined edges and presence of acid fast bacilli in the lesion, 
(AFBs) [2]. Despite this first report, the name BU originated later as a consequence of the 
discovery of a large numbers of cases in the Buruli County (Nakasongola Disctirc) in Uganda, 
during the 1960s [3]. In the same period and in the following years, a significant number of 
cases were reported from other West and Central African countries including the Democratic 
Republic of Congo, Nigeria, Gabon, Cameroon and later also from Benin and Ghana [4–8]. 
Since new cases and foci of BU were progressively found not only in Africa and Australia but 
also in countries in South America and in South East Asia, in 1998 the WHO initiated the 
global BU initiative with the aim to disclose this emerging topic and to control and coordinate 
research activities [9]. Currently BU is reported from over 30 countries all around the world 
(Figure 1), being a concrete and relevant public health problem [10]. In 2014, 12 out of the 15 
countries reporting regularly to WHO, stated around 2200 new cases, more than half of cases 
reported in 2009 [11]: a part for few countries, the trend of the number of cases seems to 
progressively decline but the reasons behind are not yet elucidated [12]. Considering the fact 
that BU is typically a disease of people living in remote areas with limited access to health 
infrastructures, insufficient data collection and reporting systems and also strong traditional 
beliefs, the real number of the cases reported is still an issue and it could be anunderestimat 
[13]. Buruli ulcer disease is characterized by a focal distribution, generally associated with 
rural wetlands or areas in which stagnant water is present so it seems to be directly related to 
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environmental factors [14,15]. It can affect individuals of all ages but in African countries it 
occurs mostly in children and young adults between the age of 5 and 15 and in individuals 
over 50 years while it is under represented in children below the age of 5 [16–18]. The typical 
localization of the lesions is on the limbs and particularly the lower ones and no differences 
between genders are observed in terms of BU incidence [14,18,19]. 
 
 
Figure 1: A global map representing the countries which reported case in 2014. Data source, 
                World Health Organization global Health Observatory Map Gallery   
 
 
1.1.1 BU in Cameroon 
In Cameroon BU was described for the first time in 1969, in cases coming from the Nyong 
River valley, in the Central region of Cameroon close to the villages of Akonolinga and Ayos 
[20]. After this first description, between the beginning of 2000 and 2009 suspected cases 
were also reported from the Bankim Health District (HD) in the Adamawa region [21]. 
Currently in Cameroon there are 3 major endemic foci for BU: Ayos/ Akonolinga/ Ngoantet 
in the central region of Cameroon, Bankim in the Adamawa region and Mbonge in the south 
West region (A. Um Book, personal communication). The district of Bankim, is believed to 
have become a BU hotspot after large alterations of the environment when in 1989 an 
artificial lake, the Mapé dam basin, was created by damming the Mbar River (A. Um Book, 
personal communication) [22]. The Bankim HD in the Mapé Dam region of Cameroon in 
which our activities were carried on from 2010 to 2014, consists of 7 health areas (Atta, 
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Songkolong, Somié, Nyamboya; Bamkin Rural and Urbain, Bandam) and is bordered by 4 
other HDs (Nwa, Malantuen, Mayo Darlé and Yoko). Main geographical features of the area 
are the artificial Mapé Dam described above and the Mbam River which is creating a natural 
border between the Bankim HD and the Yoko HD (Figure 2) [18]. In Cameroon, the National 
BU Control Program (NBUCP) was initiated in 2002 sharing the aim of the GBUI declaration 
established by the WHO. It was built up in collaboration with the NGOs FAIRMED and MSF 
Switzerland with the objectives to detect cases early, confirm 70% of clinical BU suspected 
cases by PCR, treat all active BU cases and heal at least 95% of BU cases in order to reduce 
the suffering of the affected population (E.T. Njih, Plos NTD under review). The national BU 
program included the implementation of BU diagnostic and the opening of treatment centers 
(BU-DTCs) in the main cities and in the periphery to provide adequate infrastructure and 
trained health personnel in the BU endemic areas. 
 
 
Figure 2: Bankim Health District in the Adamawa region of Cameroon. 
Figure curtsy of Martin W. Bratschi. 
 
 
In the Bankim HD the health infrastructure consists of a public district hospital in Bankim, the 
reference center for the treatment of BU, and 6 public and 4 private primary health centers 
with personnel trained to take care of BU patients. 
The remote and poor nature of this district contributes to another important characteristic 
associated to the described area which is the strong traditional and belief component. To seek 
treatment at traditional healers close to the villages and the use of traditional remedies is 
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common. Additionally the skeptical approach to the hospital and current chemotherapy or 
surgery, makes the management of this disease in the described area, particularly challenging 
(Awah PK personal communicate). 
 
 
1.2 Causative Agent 
1.2.1 Genetic diversity of M. ulcerans  
The pathogen M. ulcerans is believed to have evolved from the ancient progenitor M. 
marinum, an aquatic pathogen which causes granulomatous lesions in fish and occasionally 
also skin lesions in humans. Despite the two mycobacteria share more than 97% overall 
nucleotide identity, M. ulcerans is more virulent and causing the human disease Buruli ulcer 
[23]. 
The difference between the two species is mainly due to the major changes acquired by M. 
ulcerans during the evolution and the divergence from M. marinum [24]. Specifically the 
genetic differences characterizing M. ulcerans are the acquisition of the pMUM001 mega-
plasmid of 147 kb encoding for the polyketide synthesis system responsible for the production 
of mycolactone, which is involved in the pathogenesis of BU disease, as well as acquisition of 
two insertion sequences (IS) [25,26]. The insertion sequences (IS) IS2404 and IS2606 are 
genetic sequences used to differentiate mycolactone-producing mycobacteria MPMs from M. 
marinum and they are used as targets for the M. ulcerans specific polymerase-chain reaction 
(PCR), the current most sensitive diagnostic tool for BU [27–29]. The acquisition and the 
expansion of these two sequences have led to extensive pseudogene formation and genome 
rearrangement [23]. In addition, during the evolution, M. ulcerans also has undergone genome 
reduction and rearrangement by gene deletion suggesting an adaptation to a new ecological 
niche in the environment, different from the one of its ancestor [19,30].  
The discovery of other mycobacteria not associated to BU but also producing mycolactone 
isolated from fish (M. solariae, M. pseudoshottsii) and frog (M. liflandii), enhanced the 
hypothesis that they developed from M. marinum. Over time, M. ulcerans diverged into two 
different lineages namely “ancestral” and “classical”. M. ulcerans isolates from Australia and 
Africa are included in the “classical” linage while strains from Japan, China and South 
America represent the “ancestral” linage. 
Genetic analyses of different M. ulcerans strains causing disease in humans revealed that the 
pathogen is highly clonal and high resolution typing methods have to be used to differentiate 
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strains circulating in the same endemic area in order to gain knowledge about spatial-temporal 
spread of genetic M. ulcerans variants [31–33].  
1.2.2 Mycolactone 
M. ulcerans produces a macrolide exotoxin called mycolactone which is considered to be the 
key virulence factor of M. ulcerans responsible for the majority of the pathology related to 
BU disease, including the characteristic necrosis of the subcutaneous tissues. 
The secreted exotoxin is able to passively diffuse through the membrane of cell inducing 
necrosis and apoptosis [34,35] additionally it is responsible for the suppression of the host 
immune response by acting on the adapted cell mediated immunity and as well as the innate 
immune response. By doing so the progression of the disease is promoted [36,37]. 
Macrophages, monocytes, B-cells and T-cells are partially blocked via the suppression of 
interleukins, tumor necrosis factor-α (TNF-α) and interferon-γ (INF-γ) [34,38,39]. 
Different M. ulcerans strains produce different closely related forms of mycolactone which 
display differences in the general structure and have a defined geographical pattern. The 
chemical variability between the 5 forms (A/B, C, D, E and F) is mainly based on the 
heterogeneity of the lower side chain which can vary in length, number of double bonds or 
number and position of the hydroxyl groups, in contrast with the macrolide core and the upper 
side chain which maintained conserved structure [40,41]. According to these structural 
differences and the geographical clustering, five different variants of mycolactone have been 
identified among a worldwide collection of strains; mycolactone A/B is produced by isolates 
from Africa while isolates from Australia and South Asia respectively produce the C form and 
the D form of mycolactone. Different forms of mycolactone seem to be associated with 
different virulence and mycolactone A/B appears to be the most potent [40,42]. In addition to 
the mycolactones produced by the human M. ulcerans phatogen two other variants, E and F, 
are found to be produced by the fish pathogen (M. pseudoshottsii) and the frog pathogen (M. 
liflandii), also called mycolactone producing mycobacteria (MPM) [37]. Recently for research 
purposes, synthetic mycolactone forms have been produced with the aim to have more insight 
into the structure-activity relationship [43].  
 
 
1.3 Natural Reservoir and Transmission 
Both, natural reservoir and transmission of M. ulcerans are poorly understood and still under 
investigation. Despite this, it is commonly assumed that endemic foci are associated with 
wetlands, areas with slow flowing or stagnant water and more recently also with proximity to 
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rivers indicating human behavior associated with water as a risk factor. Behavioral studies 
disclosed that living, swimming and working close to water, the failure to wear protective 
cloths, poor wound care, and agriculture activities are risk factors [19,44–46]. Increased BU 
incidence has also been associated to human interventions like damming of rivers, 
deforestation, increased agriculture activities but also to natural events which created 
unprecedented wetland modifying the environment and causing relevant effects on the 
organization and function of preexisting ecosystems [19,47,48].  
While it is known that other closely related human mycobacteria including M. tuberculosis 
and M. leprae are characterized by person to person transmission, for M. ulcerans this is still 
not clear and it is hypothesized that it is acquired through environmental contact [19]. Human 
to human transmission is exceptionally rare with just one case reported and occurred 
following a human bite [49]. In addition to the hypothesis of the environmental acquiring, 
others routes and mechanism of transmissions have been proposed and investigated over the 
years ranging from aerosol contaminations to vector transmission by amoebae and snails, 
water bugs or other insects biting human [50–53]. Aquatic networks-interface forming 
biofilms which create an optimal microhabitat for the bacterium, have also been investigated 
and it was speculated that they could confer selective advantages [54]. Although the potential 
of different African aquatic bugs to serve as environmental reservoir has been shown, direct 
transmission by biting has never been demonstrated. So far DNA of M. ulcerans was only 
detected in African invertebrates which are not hematophagous [19,52,55]. In contrast to 
Africa, in Australian people have less direct contact with the environment and it is also know 
that tourists can be at risk, so in these areas, alternative routes of transmission have been 
investigated. Examples of strong correlation between incidence of BU cases and incidence of 
vector borne infections transmitted by mosquitos (Ross River Virus / Barmah Forest Virus) 
have been reported and effectively M. ulcerans DNA was identified in mosquitos captured 
during a BU outbreak in southern Australia [56]. In addition to this, more recently, Fyfe et al. 
found M. ulcerans positive skin lesions and/or feces in possums, small terrestrial marsupial, 
captured at Point Lonesdale, one of the endemic focus in Australia which might serve as the 
reservoir [57,58].   
Despite the presence of sensitive PCR techniques which are able to detect very small amounts 
of M. ulcerans DNA in the environmental samples, it is so far not possible to determine if 
viable bacteria are present. Considering these limitations and the few positive samples found 
in highly endemic BU countries, results of environmental studies are difficult to interpret and 
they have therefore to be taken with caution [19,29].  
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In recent times a number of studies in highly endemic communities have been realized, but 
more studies targeting local populations and their behavior could be an approach to get more 
insight in the transmission issue. To identify the mode of transmission and the natural 
reservoir, could lead to the development or implementation of preventive measures to protect 
and reduce the impact of this disease among the populations at risk. 
 
.     
Figure 3: A typical swampy area in Cameroon where BU is present. 
 
 
1.4 Pathogenesis 
1.4.1 Clinical presentation 
BU presents with a spectrum of clinical forms ranging from non-ulcerative stages to the 
presence of large open ulcers. It is generally assumed that early lesion are represented by the 
nodular or edematous form which can eventually progress to ulcers characterized by 
undermined edges and cotton wool like appearance [13,59]. Lesions are usually classified 
according to the WHO criteria on the basis of the lesion size: Category I (small lesion <5 cm), 
Category II (5-15 cm of diameter) and Category III (single lesion > 15 cm of diameter, 
multiple lesions or lesions at critical sites such as eye, breast and genitalia, osteomyelitis) 
[60]. Unless secondary infection due to other bacteria which can infect the lesion, most ulcers 
are painless probably as a consequences of the nerve damage caused by the toxin at the site of 
the lesion [61,62]. Despite the fact that the majority of the lesion are reported to occur at the 
extremities, any part of the body can be affected [63]. The incubation time can vary between 
few weeks up to years; patients, especially in Africa, usually present quite late at the hospital 
or at the health center showing large ulcerations which can lead to serious consequences 
including a very long stay at the hospital and lifelong disabilities like contractures, scarring 
and in the most severe cases even amputation [64,65]. Approximately 10% of the reported BU 
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cases, manifest severe conditions consisting of multiple lesions or the development of 
osteomyelitis with bone involvement [66,67]. 
A peculiar phenotypic characteristic of M. ulcerans is the very low optimal growth 
temperature ranging from 28ºC to 30ºC [15]. This restricted growth temperature plays a role 
in the pathogenesis of the BU disease by limiting the involvement of the tissues to cooler 
areas [15].  
 
 
Figure 4: Clinical forms of BU. Typical presentation of a nodule (A), Oedema (B), plaque (C) and   
                ulcer (D). Images are adapted from the WHO web site. 
 
 
1.4.2 Histopathology and Immunity  
Typically, the histopathological features present in the tissue sections from untreated BU 
patients include an extensive necrotic and edematous subcutaneous area, in which fat cell 
ghosts and limited infiltration surrounding the remaining blood vessels are present. Epidermal 
hyperplasia is also characteristic while the dermis appears with relatively intact collagen and 
reduced infiltration around glands and vessels as shown in Figure 5 [68,69]. 
 
 
Figure 5: Histopathological feature of untreated BU lesion (Source: Ruf MT et al, 2011, Plos NTD)  
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The clinical and histopathological features of BU suggest an immunological spectrum of host 
responses over time. In early stages mycolactone induces death of the tissue and strongly 
suppresses the immunity of the host. In contrast, in latest stages and during the administration 
of antibiotic treatment, leukocyte infiltration and granuloma formation can be observed and 
the host immune system might overcome the action of the toxin allowing the commencement 
of the healing process (Figure 6). 
Bacteria are generally visible in the necrotic subcutaneous area as extracellular clusters, 
typically focally distributed, but according to this immunological spectrum, as the lesion starts 
to heal, lymphoid aggregates and granulomatous inflammation develop and they start to 
destroy bacteria which then can be found intra-cellular also as debris [70–72]. 
 
 
Figure 6: Histopathology of a BU lesion after antibiotic treatment (Source: Ruf MT et al, 2011, Plos   
                NTD) 
 
 
1.5 Diagnosis 
Diagnosis of BU in rural areas is often only based on clinical signs, in order to confirm the 
clinical suspicion, although WHO strongly recommends to reconfirm the diagnosis by 
laboratory testing [27,73]. The clinical diagnosis of BU, even if done by trained and 
experienced health staff, can be complex not only for the ulcerative forms, but even more for 
the pre-ulcerative forms. Differential diagnosis for BU includes tropical ulcers, necrotizing 
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fasciitis, diabetic or venous ulcers, yaws and also cutaneous tuberculosis for ulcerative forms, 
while pyogenic abscess and cellulitis can be confused with nodule and edematous forms 
[27,74]. BU ulcers display certain specific signs like undermined edges, presence of cotton 
wool and the absence of fever and pain which can help with the differential diagnosis [75]. 
According to WHO, cases require two positive laboratory results even if in in presence of 
high clinical suspicion, one positive test result is enough [76]. 
In order to achieve reliable laboratory results, specimen sampling is a very important step and 
different methods are used for different BU forms. Pre-ulcerative lesions are typically 
sampled by fine-needle aspiration (FNA) while ulcers can be sampled by using a cotton wool 
swab to swab the undermined edges of the whole lesion. Specimens from both methods can 
be used for culturing, direct AFB staining and IS2404 PCR. For histopathology punch 
biopsies or surgical excision are needed [77]. 
Currently the four laboratory diagnostic methods available for BU are direct smear 
examination, PCR, histopathology and culture of M. ulcerans (Figure 4) [59]. 
Direct smear examination of swab specimens taken from the undermined edges of the ulcers, 
is a rapid method where acid fast bacilli (AFB) are detected after staining with Carbol fuchsin 
(Ziehl-Neelsen Method). Analysis is done with a simple light microscope. It is a simple and 
cheap method which doesn’t require sophisticated equipment making it particularly 
appropriate to use locally in limited resources countries. However, the sensitivity is quite low 
(< 60%) hence, the presence of few bacteria can remain undetected and lead to the generation 
of false negative results. Also specificity is low, due to the fact that there are other 
mycobacteria which might cause skin lesions and are detected by Ziehl-Neelsen staining [77]. 
Further, the reliability of the results is strictly dependent to the quality of the sampling 
performed and the capacity of the laboratory personal to appropriately stain and read the 
slides. 
On the other side, histopathology, culture and PCR require a good laboratory infrastructure, 
specific and expensive equipment and highly qualified personnel making those three 
additional methods not applicable in the field but only in reference laboratories. 
Histopathology can be performed either on small punch biopsies or on surgical debridement. 
There are typical histopathological features associated with M. ulcerans infection: necrosis of 
the subcutaneous tissue with appearance of fat ghost cells, edema, epidermal hyperplasia, 
reduced infiltration and also clusters of extracellular bacteria [69,70]. Because typically 
bacteria are located deep and very focal in the subcutaneous layer, AFBs may not be present 
in all histopathological specimens. To obtain an adequate histopathological sample, tissue 
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needs to consist of all the three skin layers (epidermis, dermis and subcutis), which is one of 
the major challenges associated with this method. In addition, histopathology is useful to gain 
deeper insight into the general state of the tissue and also to monitor the course of the 
treatment studying the local immune response [78].  
Similarly, the culture of M. ulcerans, is difficult and time-consuming and has a sensitivity 
between 20-60% according to the laboratory performing the assay [59]. However it is the only 
method which can distinguish between viable and dead bacteria and can therefore be used to 
monitor the treatment response and the development of drug resistance [59]. Currently, 
quantitative real time PCR (qPCR) of M. ulcerans DNA based on the amplification of the 
insertion sequences (IS) IS2404 and IS2606, is considered to be the gold standard method and 
is largely used in national and international reference laboratories. qPCR is highly sensitive 
and specific but requires strict and very frequent quality control to ensure the accuracy of the 
results [79].  
Due to limited access to treatment centers and laboratory services, the development of novel 
point of care diagnostic tests which are easy and cheap to use in remote rural areas to 
reconfirm the clinical diagnosis, is of high priority. Different strategies to face this need are 
currently being developed, including the detection of M. ulcerans DNA by the loop-mediated 
isothermal amplification (LAMP) technique, and the detection of M. ulcerans antigens by an 
antigen capture assay [80–82]. The cell wall-associated protein MUL_3720 has been 
identified as a promising target for an antigen capture assay [83]. A panel of high affinity 
antibodies against this antigen was generated and a sandwich-ELISA format with a sensitivity 
rate comparable to that of microscopic detection of acid fast bacilli in smears from clinical 
specimens was developed. Preliminary results show that this approach has great potential to 
be developed into a field-compatible point of care diagnostic test for M. ulcerans infection 
(personal communication G. Pluschke). 
 
 
1.6 Treatment 
Until 2004, BU was traditionally treated by wide surgical excision of the lesion including a 
large margin of healthy skin surrounding the necrotic area to try to reduce the rate of relapses. 
Generally skin grafting to facilitate the closure of the lesion had been necessary afterwards 
[13,84,85]. Despite these measures, relapses occurred often (in around 17% of the patients) 
leading to multiple interventions and long periods of hospitalization and rehabilitation [13]. In 
response to successful pilot studies evaluating the efficacy of a combined antibiotic regimen 
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with rifampicin and streptomycin (R/S), in 2004 WHO published a provisional guidance on 
the role of specific antibiotics in the management of Mycobacterium ulcerans disease [86]. 
Although initial doubts, R/S therapy appears to be effective in the treatment of all forms of 
BU lesions, achieving almost recurrence-free healing (0-2%) and acceptable levels of side 
effects [87,88]. Currently the standard antibiotic treatment recommended by WHO, includes 
the daily administration of oral rifampicin at 10 mg/kg and intramuscular streptomycin at 15 
mg/kg for 8 weeks. Despite the efficacy of the antibiotic treatment to kill the pathogen, 
debridement and skin grafting are often also required particularly for large lesion to speed up 
and facilitate the healing process achieving the best functional result possible [89]. Because 
streptomycin is administrated by injection and due to its side effects which are infrequent but 
indeed present especially in children, efforts are ongoing to establish a fully oral therapy by 
replacing streptomycin with other molecules. Clarithromycin seems to be an effective 
alternative and it is for instance successfully used in combination with rifampicin to treat 
pregnant women [90,91]. In addition, in Australia and French Guyana the antibiotic treatment 
regime currently used is comprised of oral rifampicin at 10 mg/kg daily and oral 
clarithromycin at 7.5 mg/kg twice a day for 8 weeks [60,92]. Identification of new compounds 
active against M. ulcerans remain a priority and research activities are strongly encouraged 
also because rifampicin, the most effective drug against BU, is also one of the first line drugs 
for the treatment of tuberculosis which might lead to the development of resistances. In all 
instances, even if the antibiotic treatment is highly effective, wound care which is being 
recognized to play an important role in BU care, together with physiotherapy is fundamental 
to prevent disabilities and life-long sequela especially when lesions are located at joints 
[93,94]. Despite the effectiveness of the treatment, it has been reported that in particular in 
very remote area, some patients initially prefer to consult traditional healers and use 
traditional herbal remedies before seeking modern medical treatments. Such practices may 
lead to worsening of the lesion conditions which can lead to prolonged wound care treatment, 
delay in healing and increase the possibility of long-term disabilities [95]. Alternative 
treatments using local application of heat exploiting the temperature sensitivity of M. 
ulcerans, were suggested already during the seventies when water filled heat jackets were 
used by Meyers et al. to treat 8 patients successfully [96]. More recently, in 2009, a proof of 
concept trial with six BU patients with ulcerative lesions was realized and lesions were treated 
with bags filled with a phase change material (PCM) for up to 56 days. These bags can reach 
a temperature of around 40ºC, for several hours [97]and can be applied without the need of 
electricity onto the lesion. All patients were cured and lesions healed by the application of 
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heat packs alone. Based on these promising results a Phase II, single center, open label, non-
comparative clinical trial with 53 patients was initiated. Results showed the efficacy of the 
local hyperthermia with a cure rate of around 92% at 6 months after completion of treatment 
[98]. 
Although it is generally held that early or uncomplicated BU lesions can spontaneously clear, 
rare cases of self-healing are reported [89,92]. 
During or after the antibiotic treatment a temporary worsening of the lesion or/and the 
appearance of secondary lesions might be experienced. This phenomenon called “paradoxical 
reaction”, is an inflammatory reaction against M. ulcerans antigens. Often this worsening is 
misinterpreted as a recurrence or relapse [99,100]. 
To date, no specific vaccine against M. ulcerans is available and the only vaccine that could 
potentially have an effect against mycobacterial diseases is the BCG (Bacillus Calmette-
Guérin) containing the attenuate bovine tuberculosis bacillus. While it is recognized that BCG 
causes a cross-protection against leprosy, no clear evidence has been reported about its 
efficacy to prevent M. ulcerans disease [101]. Despite the difficulties due to the unclear 
nature of the bacterium, the development of a new vaccine seems possible and so active 
research is ongoing in this area [102]. 
 
 
1.7 Wound healing  
One of the major problems associated with BU is the evolution of the lesions which can be 
very different from one patient to another. Some of the lesions are healing very fast following 
a normal wound healing process while others require a lot of time leading to several problems 
included high cost for care and hospitalization and also lifelong sequaela [61,103].  
Wound healing per se is a complex process, consisting of integrated phases: homeostasis and 
inflammation, tissue replacement and tissue remodeling which are characterized by inter and 
intra-cellular level variations [104,105]. Once the clotting cascade occurred, inflammatory 
cells migrate into the wound bed and promote the inflammatory phase, consisting of 
infiltrating macrophages, lymphocytes and neutrophils which clean the wound area, release 
cytokines to induce inflammation and to stimulate fibroblasts, keratinocytes and other 
components involved in the following phases of the wound healing process [106]. The tissue 
replacement phase is characterized by epithelial proliferation and migration through a 
‘‘temporal’’ extracellular matrix (ECM) composed of different proteins including fibronectin, 
tenascin and pro-collagen which act as a support for the fibroblasts migrating into the wound 
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bed. Fibroblasts together with endothelial cells support capillary growth and formation of 
granulation tissue. Myofibroblasts, which are specialized fibroblasts, are the main producers 
of collagen in healing wounds [107]; by contracting ,using α-smooth muscle actin (αSMA), 
they promote the shrinkage and the closure of wounds [108]. After the healing is completed, 
the myofibroblasts are normally eliminated and their persistence in wound granulation tissue 
is considered pathological [109]. The final remodeling phase of wound healing consists of 
few modifications including the reduction in the number of newly formed vessels to slowly 
return to conditions similar to healthy skin tissue [110].  
 
 
 
Figure 7: Phase transition in a normal wound healing process (Source: Wells A.et al, 2015, MATBIO)  
 
 
1.7.1 Wound Healing Markers 
In order to investigate the wound healing process in BU and in particular the causes 
interfering the normal course of the healing process, it is possible to use biological markers 
recognized to be important in this process which are the following ones.  
Cytokeratin 16 is expressed in the epidermis and is a marker for keratinocyte hyper-
proliferation which is one of the characteristic histopathological features in BU lesions; it is 
not present in healthy epidermal skin [111]. 
Pro-Collagen I is the main component of connective tissue; In normal skin it is found in 
limited quantities in the dermis and subcutis but during the wound healing process the amount 
can strongly increase especially in the subcutaneous tissue [112]. 
Tenascin together with Fibronectin, are extracellular matrix proteins which show a patchy 
distribution in the dermis, in the epidermal adnexa and mesenchymal structures in healthy 
skin. During the wound healing process Tenascin is upregulated in the vessels and also in the 
subcutis where increased amounts of Fibronectin are also present [106]. 
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α-SMA is a differentiation marker of smooth muscle cells and in healthy normal skin is 
generally present in the walls of blood vessels. It is commonly used as a marker for the 
detection of myofibroblasts which show, in healing wound tissues, a strong expression 
[108,113]. 
Phosphorylated S6 Ribosomal protein (PS6) is a component of the mTor pathway which is 
the mammalian target of rapamycin involved in the regulation of many major cellular process 
including growth, proliferation and death of cells and it is also implicated in pathological 
conditions. PS6 it is a marker for the activation of the mTor pathway which can be used to 
detect activated cells in a tissue [114–116]. 
Cleaved Caspase-3 is a critical executor of apoptosis and it is responsible for the proteolytic 
cleavage of many key proteins. It can be used to monitor the process of elimination of cells 
which are no longer required from one to another phase of the wound healing process 
promoting the tissue regeneration and the wound healing [117,118]. 
 
 
1.8 Skin diseases related to Buruli ulcer 
The ulcerated BU lesions, especially the ones which are very big or located at the joints, often 
present complicated and long wound healing and often require a grafting intervention to heal. 
During the lesion closure process, it may happen that scar formation results in an uncontrolled 
development of the tissue which leads to fibroproliferative diseases such as keloids or 
hypertrophic scars (HTS). These kinds of scarring problems have been documented in the BU 
disease and they may lead to severe contractures, deformities or thickened skin associated 
with lifelong disturbances [119].  
 
1.8.1 Keloids and Hypertrophic scars 
Keloids and Hypertrophic scars are a fibrous tissue overgrowth that results from an abnormal 
wound healing process and they generally develop in response to a trauma even if a 
spontaneous appearance cannot be completely excluded [120]. HTSs are described as elevated 
scars that do not spread beyond the wound margins and they can often regress naturally over 
time. They mainly contain type III collagen orientated parallel to the epidermis and organized 
in filaments. In contrast keloids continue to evolve and they are characterized by a thinned 
epithelium which can even brake and create focal ulcerations [121]. Keloids are characterized 
by an excess deposition of ECM proteins, primarily disorganized type I and III collagen and 
α-SMA in the form of myofibroblasts; in addition increased angiogenesis, overexpression of 
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cytokines and inflammatory cell infiltration has been observed [120,122]. The mTor pathway 
is known to be involved in the overproduction of ECM proteins and therefore might be up 
regulated in other inflammatory fibroproliferative diseases as HTS.  
 
Other diseases not caused by an altered wound healing process but indeed characterized by 
abnormal growth and presentation of the epidermis are inflammatory skin diseases which 
include psoriasis and atopic dermatitis (AD).  
 
1.8.2 Psoriasis and Atopic Dermatitis  
Psoriasis and atopic dermatitis (AD) are chronic inflammatory skin diseases associated with 
immunological alterations. Although AD and psoriasis are clinically and pathologically 
different they share common features like scaly skin and altered epidermal differentiation and 
both are associated with a high burden of morbidity and stigmatization [123]. Psoriasis is 
characterized by infiltration of inflammatory cells into the dermis and epidermis with 
hyperproliferation and abnormal keratinonocyte differentiation accompanied with hyper-
activation of the innate immunological cells which lead to a thickened epidermis [124,125]. 
AD is typically found in children and is also characterized by an inflammatory status of the 
upper skin layers resulting in incomplete differentiation of the epidermis [126]. While it is 
known that the mTOR pathway plays a role in the pathogenesis of psoriasis and also that 
clinical data suggest that mTOR inhibitors provide therapeutic benefit for this disease, less is 
known about the potential involvement of this important factor in other more general 
epidermal inflammations like AD [125,127].  
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2.1 Goal 
The aim of this thesis was to contribute to the understanding of M. ulcerans transmission and 
its clinical epidemiology through a five-year longitudinal study in the Mapé Basin of 
Cameroon. We further aimed to monitor the antibiotic treatment outcome for BU lesions 
using immunohistochemical approaches. 
 
2.2 Objectives  
1. To study the presence and distribution of M. ulcerans DNA in the environment at sites 
of contact of laboratory reconfirmed patients  
2. To conduct a comprehensive epidemiological and spatial distribution analysis of the 
evolution of BU over time in the Mapé Basin of Cameroon  
3. To develop a protocol for a set of antibodies targeting wound healing markers and to 
investigate the healing process of BU lesions and in particular the factors affecting the 
normal evolution of the healing process 
4. To histopathologically examine scarring conditions within the wound healing process 
of confirmed BU lesions 
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Abstract 
Buruli ulcer (BU), a neglected tropical disease of the skin and subcutaneous tissue, is caused 
by Mycobacterium ulcerans and is the third most common mycobacterial disease after 
tuberculosis and leprosy. While there is a strong association of the occurrence of the disease 
with stagnant or slow flowing water bodies, the exact mode of transmission of BU is not 
clear. M. ulcerans has emerged from the environmental fish pathogen M. marinum by 
acquisition of a virulence plasmid encoding the enzymes required for the production of the 
cytotoxic macrolide toxin mycolactone, which is a key factor in the pathogenesis of BU. 
Comparative genomic studies have further shown extensive pseudogene formation and 
downsizing of the M. ulcerans genome, indicative for an adaptation to a more stable 
ecological niche. This has raised the question whether this pathogen is still present in water-
associated environmental reservoirs. Here we show persistence of M. ulcerans specific DNA 
sequences over a period of more than two years at a water contact location of BU patients in 
an endemic village of Cameroon. At defined positions in a shallow water hole used by the 
villagers for washing and bathing, detritus remained consistently positive for M. ulcerans 
DNA. The observed mean real-time PCR Ct difference of 1.45 between the insertion 
sequences IS2606 and IS2404 indicated that lineage 3 M. ulcerans, which cause human 
disease, persisted in this environment after successful treatment of all local patients. 
Underwater decaying organic matter may therefore represent a reservoir of M. ulcerans for 
direct infection of skin lesions or vector-associated transmission. 
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Summary 
Buruli ulcer (BU) is a neglected tropical disease caused by Mycobacterium ulcerans which 
affects mainly children in West Africa. Although it is commonly believed that the infection 
originates from an environmental source, both the reservoir of M. ulcerans and the mode of 
transmission to human patients remain to be elucidated. Previous investigations indicated that 
transmission likely takes place away from the homes of patients. We therefore screened the 
farms as well as village and farm water locations of 46 laboratory confirmed BU patients of 
the Mapé Basin of Cameroon for the presence of M. ulcerans DNA by real-time PCR. In this 
analysis three positive village water locations were identified. By studying one of these 
locations in great detail we found that M. ulcerans DNA persists in underwater detritus in one 
section of the village water location even after all local cases had been treated. The detritus 
may represent a reservoir of M. ulcerans from where infection could take place through either 
direct contamination of skin lesions or through contamination or colonization of insect 
vectors. 
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Introduction 
Buruli ulcer (BU) is a neglected tropical disease of the skin and subcutaneous tissue caused by 
the environmental pathogen Mycobacterium ulcerans. The disease, which can affect all age 
groups and both sexes, has been reported in over 30 countries but is most frequent in West 
Africa. Typically, BU presents with ulcers with undermined edges but clinical manifestations 
also include nodules, oedema and plaques. Lesions can encompass entire limbs if patients 
report late for treatment [1]. The WHO recommends that all cases should be laboratory 
confirmed by microscopy, polymerase chain reaction (PCR), primary culturing or histology 
[2]. However, because of the limited access to laboratory facilities in BU endemic areas, cases 
are often diagnosed based only on clinical signs and there is a pressing need for a simple, 
sensitive and specific point-of-care diagnostic test [3]. Historically, BU was treated using 
wide scale excision of the lesions. Since 2004, the WHO recommends a combination therapy 
of daily streptomycin and rifampicin for 8 weeks as the standard treatment for BU [1]. 
In Africa, the major risk factor for BU is proximity to stagnant or slow flowing water, but 
other factors such as poor wound care, and failure to wear protective clothing have also been 
identified in case-control studies [4]. It has further been reported, that man-made 
modifications of the environment may increase the incidence of BU [4]. Despite relentless 
efforts, both the reservoir and the exact mode of transmission of BU remain a mystery. 
Numerous investigations of the environment have attempted to identify the source of the 
pathogen with so far only limited success. Studies in Ghana and Benin, have examined 
environmental samples for the presence of the M. ulcerans insertion sequence (IS) 2404. 
Some of these studies have identified many IS2404 positive sites and found positive samples 
in both BU endemic and non-endemic areas [5]. On the other hand, a study from Ghana has 
reported that only very few samples were real-time PCR positive [6]. These difficulties to 
conclusively identify the environmental reservoir of M. ulcerans and the fact that 
investigations on its genome have revealed that the pathogen has undergone substantial niche 
adaptation [7,8], have led investigators to look for invertebrate or vertebrate animal reservoirs 
[4,7]. Specifically the role of aquatic insects as potential reservoirs has been evaluated [9,10] 
and a recent study analyzing transmission networks has found that a specific taxa of aquatic 
invertebrates may be involved in the transmission of BU [11]. While to date no mammalian 
reservoir has been detected in Africa, possums have been identified as an animal reservoir of 
M. ulcerans in the southern Australian BU endemic area [12]. The mode of transmission from 
an animal or environmental reservoir to human patients also remains to be elucidated. Both 
insect bites, from mosquitos or water bugs, and direct inoculation of bacteria into the skin 
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from an environmental reservoir after skin trauma have been suspected to be relevant for 
transmission [4] and several parallel modes of transmission may need to be considered [13]. 
The objective of the current study was to longitudinally monitor environmental contact water 
sources of laboratory confirmed BU patients for the persistence of M. ulcerans DNA. 
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Material and Methods 
Ethical statement 
Approval for this study was obtained from the Cameroon National Ethics Committee 
(N°041/CNE/DNM/09 and N°172/CNE/SE/2011) and the Ethics Committee of Basel (EKBB, 
reference no. 53/11). Participation was voluntary and all patients, independent of their study 
participation, were treated according to national treatment guidelines. All cases who 
participated in the study or their legal guardian provided written informed consent. 
 
 
Study area, patient inclusion and patient confirmation 
All real-time PCR confirmed cases identified in the Mapé Basin of Cameroon [13] between 
the beginning of December 2009 and the end of November 2011, were eligible for inclusion 
in this study. For definitive BU diagnosis, clinical samples were collected, DNA extracted and 
IS2404 real-time PCR performed as previously described [13–15]. Environmental sampling 
was performed between February 2011 and June 2013. 
The main water bodies of the study area are the Mapé Dam and the Mbam River [13]. The 
region experiences two rainy seasons, a short one from mid-March to mid-May and a long 
one from mid-June to the end of September, with the rest of the year being dry. 
 
 
Selection of environmental sampling locations and sampling procedures 
Patients selected for in-depth investigation were interviewed to determine where they lived 
for the year before the onset of BU. Homes of as many non-participating real-time PCR 
confirmed cases as possible were also identified and mapped. If participating patients had a 
home both in their village and at their farm, an interview was used to determine where they 
spent more time. After achieving an accuracy of less than 10m, a GPS receiver was used to 
map the patient’s home. Together with the patient, a close friend or relative, locations of 
regular environmental contact of the patient were then visited. The investigated and mapped 
locations included the patient’s farm(s) and the location(s) where she/he obtained water while 
at home (VW: village water sources) or at the farm(s) (FW: farm water sources). Locations 
used to obtain water for drinking, cooking, bathing, clothes washing and dish washing were 
visited. At all locations, soil and plant material was collected. At the water contact locations, a 
water sample was also collected. Samples collected at the farms were dry soil and plants 
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growing on dry grounds. Plant and soil samples from the water contact locations, were 
collected from either in the water, at the water’s edge or in the moist area around the water. 
Additionally, animal fecal samples were collected in the highly BU endemic village of 
Mbandji 2. Samples were collected around the homes of laboratory confirmed BU patients 
and included the feces of chickens, ducks, pigs, goats and sheep. 
At two water contact locations located in Mbandji 2 (VW12 and VW13) we performed 
repeated and in-depth sampling over a period of more than two years (Table S1). In addition 
to the samples collected at the initial time point (t=0) as described above, samples were 
collected from VW12 and VW13 at seven additional time points (t=2.1, 4.8, 7.7, 10.5, 15.3, 
20.3 and 27.4 months). At the two initial time points, samples were collected from 3 sampling 
sites at each VW location. At the remaining time points, samples were collected at 21-22 
sampling sites around VW12, with 3-5 sample replicates at each sampling site. At the same 
time points, VW13 was sampled at 14-16 sampling sites with 1-3 sample replicates collected 
at each sampling site. Details of the sampling sites and the number of replicates collected at 
each sampling site and at each time point are given in Table S1. All samples, with the 
exception of those collected at sampling sites 7 and 13, which were plants on dry soil, were 
collected from inside the water or at the water’s edge. 
At the last follow-up time point (t=27.4 months), further soil samples from inside the water 
were collected around the log at location VW12. At each sampling site 3-5 replicates of the 
same type of sample were collected. At several sampling sites on either side of the log, 
samples were repeatedly collected in the course of a few days. At sampling site 55, additional 
samples of various natures were collected. 
All environmental samples were stored at 4ºC until analysis. 
 
 
Environmental DNA extraction and real-time PCR 
From the environmental samples, DNA was extracted and real-time PCR performed as 
previously described [14,15]. Briefly, approximately 200μL of each soil, plant and fecal 
sample was transferred to a lysing tube and DNA extracted using the Fast DNA Spin Kit for 
Soil (MP Biomedicals, product number 116560-200) and a Precellys24 homogenizer (Bervet 
Bertin Technologies). From the plant samples, DNA was extracted from a mixture of leaves 
and stems and if possible roots. For water samples, 1mL was transferred to a lysing tube, the 
tubes centrifuged for 10 min (14’000 rpm), the supernatant removed and the samples then 
processed like the other samples. All samples were at least once extracted by the above 
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method. Some samples were also processed once by homogenizing them in lysing matrix E 
tubes in the presence of MT Buffer (MP Biomedicals) and Phosphate Buffered Saline (MP 
Biomedicals), pelleting debris (10 min at 14’000 rpm) and then extracting DNA from the 
supernatant with the QIASymphony (Qiagen) and the QIAsymphony DSP Virus/Pathogen 
Midi Kit (Qiagen, product number 937055). The two different extraction methods yielded 
comparable DNA quantities, as assessed by real-time PCR, when applied in parallel to 
positive environmental samples (data not shown). For each extraction, a reagent control was 
included. 
Extracted DNA (1µL of 100µL) was run twice in the IS2404 real-time PCR assays as 
previously described [14,15]. In the IS2404 real-time PCR, an internal positive control (IPC, 
Applied Biosystems) was included to detect PCR inhibition. Inhibited samples were diluted 
1/5 and 1/10 and analyzed again. In each real-time PCR run both negative and positive 
controls were included. If a sample was positive in at least one of the IS2404 real-time PCR 
assays, DNA was extracted from a second aliquot of the same environmental sample. If again 
at least one of two parallel IS2404 real-time PCR assays was positive, the corresponding 
environmental sample was considered positive for IS2404. DNA extracted from these samples 
(1 µL and 5 µL) was then subjected to IS2606 and keto reductase (KR) real-time PCR as 
previously described [14,15]. If the extracts of a particular sample, were at least once positive 
for these two additional targets, the sample was considered positive for M. ulcerans DNA. All 
IS2404 positive samples that were not positive for both of the other targets were not 
considered to contain M. ulcerans DNA and were not included in the analysis. Most of the 
real-time PCR assays were performed in a StepOne Plus Real-Time PCR System (Applied 
Biosystems) and analyzed using the StepOne Software (v2.2.2; Applied Biosystems). Only 
samples extracted using the QIASymphony as well as samples analyzed in Cameroon, were 
real-time PCR tested for the presence of IS2404 by a Mastercycler Realplex 4 ep Gardient S 
(Eppendorf) and the data analyzed by Mastercycler ep Realplex (version 2.2). 
 
 
Statistical data analysis 
Descriptive statistics were computed using R (The R Foundation for Statistical Computing; 
version 2.15.1) and RStudio (RStudio, Boston, USA; version 0.95.262). Maps were drawn in 
ArcGIS ArcMap (Economic and Social Research Institute, Redlands, USA; version 10.0). 
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Results 
Screening of environmental contact locations of BU patients for the presence of M. 
ulcerans DNA 
From December 2009 to November 2011, 67 real-time PCR confirmed cases of BU were 
identified in the Mapé Basin of Cameroon. Of these patients, 46 were selected for in-depth 
environmental contact analysis based on their origin in the southern part of the Mapé Basin 
and their availability to participate in the study. The homes and farms as well as the VW and 
FW locations of the patients were mapped (Figures 1A and 1B). The median direct distance 
between the homes and farms was 1.5 km (interquartile range = 0.6 km to 5.3 km). While 
some patients lived permanently at their farm, others travelled more than 15 km to get from 
their home to their farm (Table 1). As shown in Figures 1A and 1B, many of the BU patients 
in the southern Mapé Basin moved south and east towards the Mbam River for their farming 
activities. 
Environmental samples (171 soil, 153 plant and 109 water samples) were collected at the 
farms (n=49), FW (n=43) and VW (n=48) locations shown in Figure 1A. Of the soil and plant 
samples, 108/171 and 109/153 respectively, were collected in or around water. The remaining 
samples were collected from dry grounds. All environmental contact locations are numbered 
in Table 1; locations used by several patients are indicated by the same number. Additionally, 
pig, goat, sheep, chicken and duck fecal samples (n=24) were collected at 14 sampling sites in 
the BU endemic village of Mbandji 2 (Figure 1B). 
All environmental and fecal samples were tested by real-time PCR for the presence of the M. 
ulcerans specific IS2404 DNA sequence. Three VW locations (VW12, VW31 and VW54) 
and one duck fecal sample (F07) tested positive (Figures 1A and 1B). At locations VW31 
(Figure 1C) and VW54 (Figure 1D), soil samples collected in the moist area around the water 
wells were positive. Both of these water locations were used by one BU patient each (Table 
1). Water from VW31 was reported to be used for bathing and washing of clothing and water 
from VW54 was used for all purposes including drinking. At location VW12, used by three of 
the patients living in the village of Mbandji 2, both a soil and a plant sample collected at the 
water’s edge, tested positive. Further details on the results of a longitudinal study at VW12 
are provided below.  
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Persisting real-time PCR positivity of detritus after successful treatment of the identified 
local BU patients 
As shown in Figures 1B and 2A, six BU patients were notified during the study period in 
Mbandji 2, which is situated between the Mapé Dam and the Mbam River (Figure 1E). The 
locations of the homes of these patients are shown in Figure 2B and characteristics of the 
patients, which are not related to each other, are listed in Table 2. Patients 06, 13, and 34, 
aged 9, 5 and 57, respectively, all used the real-time PCR positive VW12 location (Figure 2B 
and Table 1). Furthermore, the only positive faecal sample (F07; from a duck) was collected 
in close proximity of the home of patient 13 (Figure 2B). The other three patients from 
Mbandji 2 used primarily four other VW locations (Table 2, Figure 2B).  
To better characterize IS2404 real-time PCR positivity in Mbandji 2, we performed detailed 
longitudinal analyses of VW12 and the close-by IS2404 negative location VW13 (Figure 1B 
and 2B). VW12 was a permanent small water body with a wooden log lying in it (Figure 3A). 
The water was shallow and flowed slowly from the left to the right when approaching the log 
from the village of Mbandji 2. For most of the log, the left and right side of the water were not 
connected under the log; however at some points water could pass underneath the log. On the 
right side of the log, the vegetation was denser and a layer of detritus was accumulating. In 
contrast, the compacted ground on the left was not covered with detritus. Location VW12 was 
used by the local population – including patients 06, 13 and 34 (Table 1 and 2) – to wash 
clothing and for bathing. For these activities, locals stood in the water on the left side of the 
log. The father of patient 13 also reported that his daughter went to this location to play. In 
contrast, VW13 was used by the local population – including again patients 06, 13 and 34 – to 
obtain drinking water as well as water for cooking and bathing. In the front section of VW13, 
where there were planks of wood (Figure 3B), water emerged from several springs. 
We collected and analysed environmental samples at eight time points over a period of 27.4 
months at both VW12 (n=635) and VW13 (n=217) (Table S1). Particularly at location VW12, 
substantial seasonal alterations of the environment over the study period were observed 
(Figure 3A and 3B). None of the 217 samples collected at VW13 tested positive in the IS2404 
real-time PCR and only one of 108 samples taken from the sand pits, which are located 
immediately to the north-west of VW12 and are part of the larger VW12 location, tested 
positive (Figure 4B and 4C, Figure S1 and Table S1). In contrast, at 7/8 time points, positive 
samples were obtained from at least one of the six positive sampling sites identified at VW12 
(Fig. 4). In particular underwater detritus samples collected at sampling site 37 were positive 
at 5/6 time points tested (Figures 4A and 4B). The average IS2404 real-time PCR Ct values of 
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the positive samples varied between 34.0 and 38.4 (Figure 4B). As shown in Figure 4C, at the 
initial sampling time point, there was still one active case of BU (patient 34) using VW12 and 
there were still a total of three active BU cases in the entire village of Mbandji 2. However, 
from the third sampling time point on, no active BU case was using VW12 and from the 
fourth time point on, no active BU case was present in the entire village of Mbandji 2 (Figure 
4C). Taken together environmental IS2404 real-time PCR positivity at the VW12 location 
thus persisted for more than one year after successful treatment of all BU patients identified in 
the village of Mbandji 2 (Figure 4). 
Having identified the deposit on the right hand side of the log lying in VW12 as an IS2404 
hotspot (Figure 4C), we analysed the soil all around the log in more detail. While compacted 
and sandy ground was found on the left, the ground was covered with decaying organic matter 
on the right hand side of the log (Figure 5A). At the eighth sampling time point we collected 
three replicates of soil samples every 1.14 m at a total of 14 sampling sites all around the log 
(Figure 5B). Using on site real-time PCR, we identified sampling site 55 (Figure 5C) as being 
positive (data not shown) and then sampled this location as well as other sampling sites 
around the log repeatedly over the next 12 days (Figure 5C). While all 59 samples collected 
on the left hand side and at the back of the log were negative, 9/62 samples from the right side 
of the log were positive. Positive samples were identified at sampling site 55 and the 
neighbouring sampling site 56 (Figure 5C) with an average IS2404 real-time PCR Ct value of 
35.8 for all nine positive samples (Figure 5C) Additional sample types, including plants, roots 
or samples from the surface of the log, collected at sampling site 55 all tested negative (data 
not shown). 
All the above mentioned IS2404 positive samples also tested positive in the IS2606 and the 
KR real-time PCR and the mean Ct difference (ΔCt) between IS2606 and IS2404 (IS2606-
IS2404) of the samples was 1.45 (95% confidence interval from 1.10 to 1.80). This ΔCt 
indicated that the obtained PCR signal is not related to lineage 1 M. ulcerans, which are fish 
and frog pathogens, or lineage 2 M. ulcerans, both of which harbor only few copies of 
IS2606, but that the PCR signal we observed likely originates from lineage 3 M. ulcerans, 
which are found in human lesions and contain 63-98 copies of IS2606 per genome [7]. 
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Discussion 
In African BU endemic areas, both the nature of the environmental reservoirs of M. ulcerans 
and the mode of transmission to humans have so far remained unclear. The physical 
environment, e.g. biofilms, and organisms such as amoeba, insects, fish and frogs have all 
been proposed as possible reservoirs for the pathogen [4]. Investigations in Southern Australia 
have identified mammals, specifically possums, as a local reservoir of M. ulcerans [12]. 
However, no such mammalian source of the pathogen has been detected in Africa thus far 
[16]. As for the transmission to humans, hypotheses include insect vectors and direct 
inoculation from the environment via small skin lesions. Parallel modes of transmission may, 
depending on the environmental and epidemiological setting, be relevant [4,13]. A recent 
review on BU transmission, found that more evidence is needed to conclude that insects are 
involved in M. ulcerans transmission [4]. Interestingly, M. marinum, the closest relative and 
ancestor of M. ulcerans, occasionally causes human infection by inoculation through small 
skin lesions which are often not remembered by the patient because of the long incubation 
period [17]. 
Although BU may occur at all ages, the relative risk for children below the age of five to 
develop the disease is lower than for older children [13,18]. This appears to apply across 
different endemic areas in Africa and may indicate that exposure to M. ulcerans is increasing, 
once children are taking up new activities away from their homes [13,19]. Such activities 
could include going to the farm to work or to water sources for household activities, to collect 
water or to play. With this in mind and since proximity to water bodies undoubtedly is a risk 
factor for BU [4], we set out to systematically test environmental, and in particular water, 
contact locations of laboratory confirmed BU patients. Specifically we collected plant, soil 
and water samples at the farms as well as village and farm water locations of patients and 
tested them for the presence of M. ulcerans DNA.  
Due to the abundance of other and faster growing microorganisms in the environment, routine 
cultivation of M. ulcerans from environmental samples has mostly failed [20] and to date only 
a single M. ulcerans isolate from a water-strider, has been reported [21]. Attempts to culture 
from our samples were not successful also because of the overgrowth by other mycobacteria. 
By PCR using pan-mycobacterial and hsp65 primers [22,23] and DNA sequencing, we 
detected species such as M. shimoidei, M. psychrotolerans and M. chubuense in our 
preparations (data not shown). Because of these difficulties, real-time PCR for IS2404 is 
commonly used to detect M. ulcerans in the environment. We applied most stringent quality 
control procedures with internal positive controls in each sample as well as negative and 
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positive controls in each real-time PCR run. Further, we only considered an environmental 
sample positive if it was positive in two separate DNA extractions. With this approach we are 
confident that the positive samples truly contain M. ulcerans DNA. We can however not 
exclude, particularly given the heterogeneity of the environmental samples, that some positive 
samples may be missed. Although IS2404 is considered a specific marker for M. ulcerans 
[24], the existence of IS2404 positive M. ulcerans ecotypes (lineage 1) that are largely 
avirulent for humans complicates interpretation of real-time PCR data and requires that 
samples are also tested for the presence of IS2606 and that the difference between the IS2606 
and the IS2404 Ct value is analyzed [7,14]. Because M. ulcerans ecotypes that cause human 
disease in Africa and Australia (lineage 3) harbor a higher number of IS2606 sequences then 
those of linage 1, the ecovars can be separated based on the IS2606 to IS2404 ΔCT [7]. All 41 
IS2404 positive environmental samples collected in the course of this study also tested 
positive for IS2606 with a mean IS2606 to IS2404 ΔCt of 1.45. This ΔCt is well below the 
ΔCt of 7 to 8 of the for humans less virulent lineage 1 M. ulcerans strains [14]. Two IS2404 
and IS2606 positive samples tested negative in the real-time PCR for the lower copy number 
virulence plasmid associated KR sequence. Both of these samples, which had relatively high 
Ct-values for the IS2404 and IS2606 real-time PCR, were not included in the list of M. 
ulcerans DNA positive samples discussed in this paper. 
Our screening of environmental contact locations of laboratory confirmed BU patients 
revealed that they travel considerable distances to get to their farms and some of the patients 
further reported to spend several months there. Molecular typing studies of disease isolates 
may help to identify if the patients were infected close to their homes or farms [25]. 
By testing environmental samples, we identified two M. ulcerans DNA positive water wells 
(VW31 and VW54) in two different villages. In a third village we identified an M. ulcerans 
positive duck fecal sample (F07) and a positive open permanent water location (VW12). 
While this rate of environmental positivity is similar to what has been found in a study from 
Ghana [6], positivity was much higher in another study also conducted in Ghana [26]. It is 
interesting to note that all three positive locations were permanent as opposed to seasonal 
water sources. Obtaining water from such water sources has previously been shown to 
increase the risk for BU [27]. The positive duck fecal sample merits further investigation to 
determine how waterfowl may contribute to the reservoir of M. ulcerans. 
At VW31 and VW54 we did not investigate the local scenario any further and cannot exclude 
the possibility that these locations were contaminated with M. ulcerans DNA from the lesions 
of patients living close to the wells. However at VW12, a water source used by laboratory 
Chapter 3. Results 
43 
 
confirmed BU patients from Mbandji 2, we observed longitudinal persistence of M. ulcerans 
DNA in underwater detritus for more than one year after successful treatment of the last BU 
patient. Continuous presence and case search in the village allowed us to detect all local cases 
and it is therefore unlikely that the source of the environmental positivity was from bacteria 
recently spread from a human lesion. Interestingly, the more sandy ground on the left of the 
log at WV12 was never real-time PCR positive for M. ulcerans DNA and even on the right 
side of the log the distribution of M. ulcerans DNA was highly focalized (Figures 4 and 5), 
with samples taken from sampling sites just a few meters apart giving different results. The 
persistent of real-time PCR positivity in the detritus is a strong indication that this micro-
environment may represent a niche environment to which M. ulcerans has adapted in the 
course of evolution from the more generalist M. marinum [7,28]. How these findings are 
related to the recently identified potential role of aquatic worms in BU transmission [11] 
should be investigated further. 
The previously described age distribution of BU patients in the Mapé Basin [13] and the here 
described findings of M. ulcerans DNA at village water sources, lead to the hypothesis that 
around the age of four both exposure to M. ulcerans and the risk of contracting BU increases. 
At this age, children are beginning to be sent to fetch water and may get in direct contact with 
the environmental source of the pathogen. Our data further suggest that, underwater detritus 
could represent a reservoir of M. ulcerans, from where infection could take place through 
either direct contamination of skin lesions or through contamination or colonization of insect 
vectors.  
  
Chapter 3. Results 
44 
 
Acknowledgments 
We would like to thank all the patients, other members of the local community and personnel 
at the local health care facilities for their invaluable help and for participating in this study. 
We would also like to thank the staff of the FAIRMED offices in Yaoundé and in Bankim, in 
particular Ferdinand Mou and Edgar Satougle for their support. Further we would like to 
thank Miriam Bolz, Patrick Bosshart, Jan Furrer and Daniel Gervasi for their help with the 
analysis of environmental samples. 
  
Chapter 3. Results 
45 
 
Tables 
Table 1: Environmental contact locations of laboratory confirmed BU patients tested for M. ulcerans DNA. 
      
      NA: not applicable 
* Water carried to farm from home 
** Location not tested by real-time PCR 
*** VW, F and FW locations are individually numbered; locations which are shared between patients are identified by 
the same number 
# Positive for M. ulcerans DNA 
Patient ID Village Water(VW) *** Farm (F) *** Farm Water (FW) *** Distance Home–F (km) 
01 VW01, VW02, VW03 F not visited FW01, FW02 NA 
02 VW04, VW05 F01 NA * 0.63 
03 VW06, VW07 F02 FW03 12.14 
04 VW08, VW09 F03 FW04, FW05 14.31 
05 VW10, VW11 F04 FW06 5.62 
06 VW12#, VW13 F05, F06 FW07 7.54; 6.19 
07 VW14, VW15, VW16 F07, F08 NA * 0.34; 0.65 
08 VW17 F09 FW08 0.69 
09 VW18, VW19 F10 FW09, FW10 3.03 
10 VW20, VW21 F11 FW11 2.27 
11 VW22 F12 FW12 1.08 
12 VW23, VW24 F13, F14, F15 FW13 5.37; 5.26; 1.40 
13 VW12#, VW13 F16 FW not visited 2.87 
14 VW25 F17 FW14 1.57 
15 VW26 F18 FW15, FW16 3.20 
16 VW27, VW28 F19 FW17, FW18 11.96 
17 VW29 F20 FW19, FW20 3.51 
18 VW30 F21 FW21 0.55 
19 VW31# F22 FW22 12.62 
20 VW32 F23 NA * 0 
21 VW not visited F24 FW23 0 
22 VW33 F25, F26 FW24 0.89;1.20 
23 VW34, VW35 F27 FW25 2.00 
24 VW36, VW37 F not visited FW not visited NA 
25 VW38 F28 FW not visited 5.66 
26 VW39 F29 FW26, FW27 1.48 
27 VW40, VW41 F30 FW28, FW29 7.32 
28 VW42, VW43 F31 FW30,FW31,FW32,FW33 4.40 
29 VW44, VW45, VW46 F32 ** FW34 3.60 
30 VW47 F33 FW35 15.35 
31 VW48 F34 NA * 0.30 
32 VW49 F35 NA * 0.99 
33 VW50 F36 FW36 1.83 
34 VW12#, VW13 F16 FW not visited 2.98 
35 VW51 F37, F38 NA * 0.08; 0.21 
36 VW52, VW53 F39 NA * 0.38 
37 VW54# F40 NA * 0.24 
38 VW55 F41 FW37 1.31 
39 VW56, VW57 F42 NA * 0.59 
40 VW58, VW59 F43, F44 FW38, FW39 1.13; 0.84 
41 VW52, VW53 F45 NA * 0.79 
42 VW60 F46 NA * 0 
43 VW61 F47 NA * 0.02 
44 VW not visited F48 FW40, FW41, FW42 5.91 
45 VW62 F49 FW43 13.52 
46 VW48 F50 NA * 0.17 
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Table 2: Laboratory confirmed BU patients in Mbandji 2 during the course of the study. 
 
Patient 
ID 
Age Gender 
Clinical 
Form 
Category 
Disease 
Start 
Date* 
Discovery 
Date 
Treatment 
Start 
VW used by 
the patient 
06 9 M nodule 1 unknown 13.04.2010 24.07.2010 
VW12 and 
VW13 
13 5 F plaque 2 11.09.2010 06.11.2010 10.11.2010 
VW12 and 
VW13 
15 2 M ulcer 3 26.10.2010 30.11.2010 03.12.2010 VW 26 
33 11 M ulcer 2 10.03.2011 05.05.2011 10.05.2011 VW 50 
34 57 M ulcer 1 01.03.2011 10.05.2011 12.05.2011 
VW12 and 
VW13 
40 42 M ulcer 3 06.09.2009 07.08.2011 07.08.2011 VW 58 and 59 
 
 * Calculated based on information provided by the patient 
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Supplementary Table S.1: Number of environmental samples collected at each sampling 
sites of VW12 and VW13 at all sampling time points. 
 
Sampling 
Site* 
Sample 
Type t = 0 
t = 2.1 
months 
t = 4.8 
months 
t = 7.7 
months 
t = 10.5 
months 
t = 15.3 
months 
t = 20.3 
months 
t = 27.4 
months 
1 water NA NA 1 3 3 3 3 3 
2 soil NA NA 1 3 3 3 3 3 
3 plant NA NA 1 3 3 2 3 3 
4 plant NA NA 1 3 3 3 3 3 
5 water 1 NA 1 3 3 3 3 2 
6 plant 1 NA 1 3 3 3 3 3 
7 plant NA NA 1 3 3 3 3 3 
8 soil NA NA 1 3 3 3 3 3 
9 soil NA NA NA NA 3 3 3 3 
10 plant NA NA 1 3 NA NA NA NA 
11 water NA NA 1 3 3 3 3 3 
12 soil NA NA 1 3 3 3 3 3 
13 plant NA NA 1 3 3 3 3 3 
14 water NA NA 1 3 NA NA 3 3 
15 soil 1 NA NA 3 NA NA NA NA 
16 plant NA NA NA NA 3 2 3 3 
17 soil NA NA 5 3 3 3 3 3 
18 water NA NA 4 3 NA 3 3 3 
19 plant NA NA 5 3 3 3 3 3 
20 plant NA NA 5 3 3 3 3 3 
21 water NA NA 4 3 3 3 NA 2 
22 soil NA NA 5 NA 3 3 3 3 
23 water 1 1 NA 5 NA NA 5 NA 
24 soil NA NA 5 NA 5 5 NA 5 
25 soil 2 1 4 5 5 5 5 5 
26 water NA NA NA 5 NA NA NA NA 
27 plant 2 3 5 NA 5 5 5 5 
28 soil NA NA 5 NA 5 5 5 5 
29 plant NA NA NA 5 NA NA NA NA 
30 water NA NA 5 5 5 5 5 3 
31 soil NA NA 5 5 5 5 5 5 
32 plant NA NA 5 5 5 5 5 5 
33 plant NA NA 5 5 5 5 4 5 
34 water NA NA 4 5 5 5 5 5 
35 plant NA NA 5 5 5 4 5 5 
36 plant NA NA 5 4 5 5 5 NA 
37 soil NA NA 5 5 5 5 5 5 
38 water NA NA 5 5 5 5 5 5 
39 plant NA NA 5 5 5 5 5 NA 
40 plant NA NA 5 5 5 5 5 5 
41 plant NA NA 5 5 5 5 5 5 
42 plant NA NA 5 5 5 5 NA 5 
43 plant NA NA 5 5 5 5 4 5 
* Sampling sites 1 to 16 are at VW13 and 17 to 43 are at VW12. 
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Figures 
 
 
 
Figure 1: Environmental contact network of laboratory confirmed BU patients from the 
southern Mapé Basin. 
Panel A and B (detailed view of the village of Mbandji 2) show the houses where the 46 
laboratory confirmed BU patients in our study lived (black points), the farm(s) where they 
worked (green points) and the locations where they obtained their water (blue points) during 
the year before the onset of BU symptoms. The home of each patient is connected with their 
farm(s) as applicable. Homes of 17 of the 21 non-participating laboratory confirmed BU 
patients were also mapped and are shown in grey. At the farms and water contact locations, 
soil (n=171), plant (n=153) and water (n=109) samples were collected. Furthermore, in 
Mbandji 2 (B), animal faecal samples were collected around patients’ houses (brown points). 
All samples were tested for the presence of M. ulcerans DNA and three village water 
locations were found to be positive (red points; VW12, VW31 and VW54). Further, at 
location F07 a positive duck faecal sample (red point) was collected. Photographs of locations 
VW31, VW54 and F07 are shown in C, D and E, respectively. Finally, Panel B also shows a 
negative water contact location (VW13) which was studied in detail. 
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Figure 2: Water contact locations in Mbandji 2 which were investigated in detail. 
Based on the high case number and the identification of two environmental locations which 
were positive for M. ulcerans DNA, water contact locations in Mbandji 2 were analysed in 
detail. The town is located between the Mapé Dam and the Mbam River (A). Panel B shows 
the locations of the homes of the 6 patients from Mbandji 2 in our study (black points) and 
each of the homes is connected with the village water location(s) used by the respective 
patient. Faecal sampling sites are also shown (brown points). Locations which tested positive 
for M. ulcerans DNA are highlighted in red (B). A positive (VW12) as well as a close by 
negative (VW13) village water locations were studied in more detail. Images are based on a 
0.5m resolution WorldView-2 image take on March 12th 2011. 
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Figure 3: Alterations of the environment at locations VW12 and WV13 at the sampling 
time points. 
Photographs of locations VW12 (A) and VW13 (B) are shown at selected environmental 
sampling time points. 
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Figure 4: Persistence of M. ulcerans at a village water location of BU patients. 
Panel A shows a diagram of the water hole at VW12A from where samples were collected at 
eight time points over a period of 27.4 months. Soil sampling sites are shown as brown 
crosses, water sampling sites as blue crosses and plant sampling sites as green crosses. Table 
S1 shows how many samples were collected at each sampling site and each time point. All 
samples were tested for the presence of M. ulcerans DNA by real-time PCR. At 7 sampling 
time points, M. ulcerans real-time PCR positive samples were identified at VW12 (B with 
positive sampling sites identified by the larger coloured circles and C). Panel C (line colours 
correspond to the circle colours in panel B) shows the rate of positivity of the collected 
sample replicates as well as the average Ct value for the IS2404 real-time PCR performed on 
the positive samples. Finally, panel C shows the number of active BU cases in the village of 
Mbandji 2 (black line) and the number of active BU cases using VW12 (red line) at the 
environmental sampling time points. 
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Figure 5: In-depth analysis of soil surrounding the log at VW12. 
Panel A shows the nature of the soil on the right and the left hand side of the log. To better 
understand positivity of samples at location VW12, we performed sampling all along the log 
on either side (B; brown crosses indicate sampling sites). Selected sampling sites were re-
sampled over the next 12 days as indicated in panel C. Panel C further shows the rate of 
positivity among the replicates collected at each sampling time point and the average Ct value 
of the IS2404 real-time PCR performed. 
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Supplementary Figure S1: Sampling sites at VW13 and the sand pits at VW12. 
Diagram of VW13 and the sand pits close to VW12 with the sampling sites; soil sampling 
sites are shown as brown crosses, water sampling sites as blue crosses and plant sampling 
sites as green crosses. For details on the main water body of VW12 (transparent part) see 
Figure 4. 
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Abstract 
Buruli ulcer (BU) is a neglected tropical disease of skin and soft tissue caused by 
Mycobacterium ulcerans. While the disease has been reported from more than 30 countries 
worldwide, most cases occur in West Africa. Here we report results of a longitudinal study on 
BU cases reporting to the health facilities of the Bankim Health District (HD) of Cameroon. 
Following a house-by-house survey in the spring of 2010, a system for continuous registration 
of new BU cases was established. Of the 274 clinically diagnosed cases between 2010 and 
2014, 148 (54%) were re-confirmed by IS2404 qPCR as BU. Locally performed microscopic 
examination detected acid-fast bacilli in 76.2% of the analyzed qPCR positive lesions. 
However, there was also evidence for false positive microscopy results. 63.5 % of the laboratory 
reconfirmed BU patients originated from the Bankim Health District, the others came primarily 
from the surrounding districts. A substantial proportion of patients lived close to the Mbam 
River or had their farms close to it. The population age adjusted prevalence showed a biphasic 
pattern with the lowest prevalence in the <4 year olds, and peak prevalence’s in the 12 to 14 
and in the <50 year olds. 43.2% of the patients had WHO category 3, 28% category 2 and 28.8% 
category 1 lesions, respectively. The mean duration before medical consultation was 27 weeks 
for category 3, 11 weeks for category 2 and seven weeks for category 1 patients, respectively. 
Taken together, our data show that 1. a point-of care diagnostic test for BU is urgently required, 
2. even well-established BU treatment centers may receive primarily patients with advanced 
lesions and 3. research on the mode of transmission of M. ulcerans should focus on agricultural 
activities.   
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Introduction 
Buruli ulcer (BU) is a necrotizing disease of skin and soft tissue caused by Mycobacterium 
ulcerans [1]. While BU has been reported from more than 30 countries worldwide, the majority 
of cases are occurring in West and Central Africa. More than 80% of all BU cases are currently 
reported from Benin, Cameroon, Côte d’Ivoire, Democratic Republic of the Congo and Ghana 
[2,3]. Within the endemic countries, cases are focally distributed in rural areas [4,5].  
BU presents with pre-ulcerative forms ranging from nodules to plaques and edema, which may 
develop into potentially large ulcers with characteristic undetermined edges [1,6]. The cytotoxic 
macrolide exotoxin mycolactone of M. ulcerans is the key factor in the pathogenesis of the 
disease [7–9]. While in African BU endemic settings, most patients are children [1], the disease 
can affect individuals of all ages [10–12]. Typically the lesions occur at the extremities, but all 
parts of the body can be affected [12]and in most settings no differences in BU incidence 
between women and men have been observed [13]. The severity of the disease is classified by 
the WHO into three categories: “Category 1” single lesions with ≤ 5 cm diameter, “Category 
2” single lesion 5-15 cm diameter and “Category 3” lesions with diameter > 15 cm, multiple 
lesions, lesions at critical sites (eyes, breast or genitals) or osteomyelitis [14]. 
Despite the WHO recommendation to use laboratory diagnostic tests to reconfirm clinical 
diagnosis, especially in rural and remote areas, many cases of BU are currently diagnosed based 
only on clinical signs and symptoms, since no sensitive point-of care test is available. 
The WHO recommended treatment for BU consists of daily administration of oral rifampin (10 
mg/kg) combined with intramuscular streptomycin (15 mg/kg) for 8 week under supervision 
[14]. Clarithromycin (7.5 mg/kg) can be used to replace streptomycin [15]. Patients who are 
not promptly managed and treated, can develop very large lesions, requiring long wound 
healing times and leading to long term functional disabilities [1,16,17]. 
Although risk factors for developing BU, such as proximity to slow flowing or stagnant water 
bodies, not wearing protective clothing and poor wound care, have been identified, the mode 
of transmission and the natural reservoir of M. ulcerans are still unknown [18]. Several theories 
have been proposed, including transmission by an insect vector or direct inoculation from an 
environmental reservoir into skin lesions[18–23]. In Cameroon, BU was described for the first 
time in 1969, in patients coming from the Nyong River valley, in the Centre region close to the 
villages of Akonolinga and Ayos [24]. In 2001 a survey in that area identified numerous cases 
of active and inactive BU [24]. Between 2007 and 2009 first suspected BU cases were reported 
from the Bankim Health District (HD), which turned out to be one of the BU endemic foci of 
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Cameroon [25,26]. On the basis of these findings, in 2010 an exhaustive house-by-house survey 
was realized in the Bankim HD and a surveillance and recording and reporting system was 
established in the area [12] to continuously monitor all cases.  In the present paper we report 
the results from the longitudinal observations covering all BU cases registered in the Bankim 
HD of Cameroon for the five year period from 2010 till 2014. 
 
 
Material and Methods 
Ethical statement 
Ethical approval for the house-by-house survey and the subsequent surveillance system was 
obtained from the Cameroonian National Ethics committee (041/CNE/DNM/09 and 
172/CSE/SE/2011) and the Ethics Committee of Basel (EKBB, reference no. 53/11). In 
addition, all patients or their guardians, if underage, signed an informed consent. All patients 
detected in the Bankim HD during the course of the study, were, regardless of their consent to 
participate in the study, treated according to the national BU treatment guidelines of Cameroon. 
 
Study area 
The study was conducted in the Mapé Dam region of Cameroon. The area consists mainly of 
the Bankim HD but also includes part of the neighboring HDs namely the Nwa HD, the 
Malantuen HD, the Mayo Darlé HD and the Yoko HD. Main environmental features of the area 
are the Mapé Dam, an artificial lake created by damming the Mapé River in 1988 and the Mbam 
River which delimits the natural border between the Bankim HD and the Yoko HD. 
 
 
Surveillance method 
After the first house-by-house survey realized in 2010 [12], a continuous surveillance system 
to monitor the occurrence of new cases of BU was established in the Mapé Basin of Cameroon. 
The surveillance approach was based on community and health personnel referrals, as well as 
on regular supervision to health centers carried out by trained and experienced health workers. 
During supervisory visits, suspected BU cases were observed and if necessary referred to the 
Bankim district hospital to be further evaluated. Prior to treatment initiation, swabs or a fine 
needle aspirate (FNA) were collected from lesions for laboratory reconfirmation. Several dry 
swabs were collected from ulcerative lesions or a FNA was drawn from non-ulcerative lesions 
and then transferred onto a dry swab to facilitate handling and storage. In addition, clinical and 
Chapter 4. Results 
  
 
61 
 
demographic information was collected from the BU patients. Geographic coordinates of the 
house where the patients lived for the year before the onset of the disease and the farm where 
they worked in the same period were collected using a Global Positioning System (GPS) 
receiver. Further, photos documenting the state of the lesions at the moment of enrolment were 
collected. All clinically confirmed cases between 2010 and 2014 were included in the cohort 
and evaluated in the presented study.  
 
Laboratory confirmation of BU cases 
Specimens from suspected BU cases were examined in the laboratory of the Bankim district 
hospital using Ziehl–Neelsen (ZN) staining for the detection of acid-fast bacilli (AFB). ZN was 
performed according to the WHO guidelines [6] and the reading was done by an expert 
laboratory technician. The rest of the swab samples were locally stored at 4ºC before being 
shipped to the Swiss Tropical and Public Health Institute in Basel, Switzerland for IS2404 
quantitative polymerase chain reaction (qPCR) analysis. The qPCR analysis was done 
according to the protocol developed by Fyfe et al. [27]. Briefly, swabs were broken into glass 
bottles containing glass beads mixed with 2 mL of PBS and vortexed for 1.5 minutes. The DNA 
was extracted from 1mL of liquid using the Roche Respiratory Specimen Preparation kit and 
QIAamp DNA Mini kit, and amplified by qPCR using the StepOnePlus system. Results were 
analyzed using the Applied Biosystem StepOne Software. qPCR-positive reconfirmed samples 
were also used to initiate a M. ulcerans primary culture on Löwensein-Jensen medium, as 
previously described [28]. 
 
Statistical analyses  
The measured outcomes and patients’ characteristics were summarized using counts and 
proportions if these were categorical and as means, standard deviations, medians and ranges if 
they were of continuous nature. The differences in categorical outcomes were determined using 
the Fisher’s exact test, and if the outcomes were continuous, the Mann-Whitney U-test or 
Kruskal Wallis tests were used. The association between binary outcomes and factors of interest 
was calculated using logistic regression models, examining first the association with single 
factors and then adjusting for other factors of interest. Results are expressed as odds ratios. The 
level of significance was set at p<0.05. SAS release 9.4 (SAS Institute Inc., Cary, USA) was 
used for the statistical analysis. Geographic data were analyzed with ArcGIS ArcMap 
(Economic and Social Research Institute, Redlands, USA; version 10.2.1)  
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Results 
From January 2010 to December 2014, 274 suspected BU cases were enrolled in our cohort in 
the Bankim HD in the Adamawa region of Cameroon, where the Bankim District Hospital is 
the referenced center for BU treatment in that area. The annual number of reported clinically 
confirmed cases of BU was variable with the largest number being registered in 2011 (n=68); 
after which a progressive decline to 41 in 2014 was observed (Figure 1B).  
Of the 274 clinically diagnosed cases 148 (54%) were re-confirmed by IS2404 qPCR. 105 of 
these 148 qPCR reconfirmed cases had also been analyzed by ZN staining at the local laboratory 
in Bankim and AFB were detected in 80 (76.2%) of these samples (Table 1). With samples 
from 136 qPCR positive patients, attempts were also made to cultivate M. ulcerans. From 45 
of the 136 qPCR positive cases (33%), M. ulcerans could be cultured. In an initial phase, 
attempts were also made to cultivate M. ulcerans from samples of qPCR negative patients; none 
of these samples yielded a positive culture. However, samples from 19 qPCR negative patients 
yielded positive ZN readings. Most likely these represented false positive results, since the 
number of ZN positive and qPCR negative results decreased after re-training of local laboratory 
staff and improvement of microscopy equipment.   
The seasonal distribution of BU cases was irregular, with the highest numbers of laboratory 
reconfirmed BU cases being reported during March, April and October (Figure 1A). The ratio 
between qPCR positive and negative cases varied throughout the year with qPCR negative cases 
dominating in February, June and August (Figure 1A). When analyzed on an annual basis, the 
qPCR reconfirmation rate was lowest in 2010 (Figure 1B). 
 
Geographic origin and movement radius of BU cases 
Of the 148 laboratory reconfirmed BU patients enrolled, 94 (63.5%) were from the Bankim HD 
with most of the others coming from the surrounding districts. Specifically, 22 patients (14.9%) 
came from the Malantouen HD, 15 (10.1%) from the Yoko HD, 9 (6.1%) from the Nwa HD 
and 1 (0.7%) from the Mayo Darlé HD. The remaining 4 patients, for whom the area of origin 
could be determined, came from further away, with one patient traveling more than 400 km 
from Douala. To obtain information on the exact origin of the patients coming from the Bankim 
and surrounding HDs (n=143), we set out to map the location of their house. This was possible 
for 136 of the patients with the remaining ones having been lost to follow-up. The distribution 
of the homes of 131 of these patients is shown in Figure 2 with the remaining five coming from 
locations not included in the area covered by the map. While BU patients originated from 
throughout the area shown in Figure 2A, clusters of patients were observed in particular in the 
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area between the Mapé Dam and the Mbam river (n=42) and in the upstream area of the Mbam 
river (n=26). Areas with these clusters are demarcated in Figures 2A. For the patients coming 
from these two clusters, we also mapped their farms to gain a better understanding of their 
movement radius. As shown in Fig 2B, all but one of the patients living in the upstream area of 
the Mbam, had their farms close to their homes and close to the Mbam river. The one patient, 
whose farm is not shown, reported to engage in farming 34 km south-west of the home. While 
some of the patients originating from the area between the Mapé Dam and the Mbam River had 
their farms close to their homes, most of them, particularly those coming from the town of 
Bakim also had their farms close to the Mbam river (Figure 2C). Satellite images (Fig. 3) depict 
that the area along the river used for agricultural activities is regularly flooded in September 
during the major rainy season. Farming takes place in these temporally flooded areas (Fig. 4). 
 
Clinical characteristic of laboratory reconfirmed BU patients  
More than half of the 148 laboratory reconfirmed patients (54.7%; n=81) were ≤ 15 years old. 
However, the population age adjusted prevalence of BU relative to the age group 0 to <2 year 
olds, showed a biphasic pattern with the lowest prevalence in the 2 to <4 year olds, and peak 
prevalences in the 12 to 14 and in the <50 year olds (Figure 5). The median age of the patients 
was 13 years (max 73 and min 0.5 years) and the mean was 22 years. Among females the 
median age was 16 years and the mean 23, while among males the median was 13 years and 
the mean 20 years. The majority of the patients (96.6%) presented with a single lesion. 
Ulcerative lesions were most common (77.6 %) followed by plaques (11%), edema (7.6%) and 
nodules (3%). 43.2% of the patients had WHO category 3 lesions, while WHO categories 2 
(28%) and category 1 lesions (28.8%) were less common. The mean duration before 
consultation was 18 weeks, 27 weeks for category 3, 11 weeks for category 2 and seven weeks 
for category 1 patients, respectively.  
Among the 148 qPCR positive patients, 36 (27.7%) were treated with antibiotics and received 
wound care and rehabilitation assistance as in-patients, while 94 (72.3%) received treatment 
and wound care as out-patients. Among the 36 patients treated as in-patients, 31 (86.1%) 
presented with a category 3 lesion, 1 (2.8%) patient had a category 2 lesion and 4 (11.1%) 
patients had a category 1 lesion. 25/148 (16.9%) patients received split skin grafting. 
Among the 148 laboratory reconfirmed patients the gender ratio was balanced with 73 (49.3%) 
females and 75 (50.7%) males. However, the gender ratio varied significantly with age with 
males dominating among younger (< 15 years) and females among the older (> 15 years) 
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patients (OR 2.6, 95% CI 1.12-6.19, p=0.025 and OR 2.49, 95% CI 0.19-0.82, p=0.012 
respectively) (Table 2).   
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Discussion 
In 2013, we reported the results of a house-by-house survey for BU, leprosy and yaws realized 
in 2010 in the Bankim HD of Cameroon [12]. The present study complements these data 
presenting results of a five-year longitudinal analysis realized in this BU endemic area of 
Cameroon. As already reported from other BU endemic areas [2], we observed a progressive 
decline of the number of cases from 2011 to 2014. The reasons for this general phenomenon 
are not yet clear. In our setting a change in the strategy for case finding over time may have 
contributed. Initially a system of active case-finding with trained teams from the Bankim 
hospital carrying out screening and sensitization campaigns all around the health district 
addressing in particular communities suspected to be at risk was established. In addition, 
community volunteers were trained to increase community participation and developing an 
interface to refer suspected BU patients to the treatment centers. With an increase in community 
awareness about BU, the active surveillance approach was gradually converted to a passive 
approach with cases coming on their own to the treatment centers. This reduction in active case 
finding activities could partially explain the observed decline in cases. However, in a recent 
small scale survey for the main skin diseases, including BU, in rationally selected communities 
in the Bankim area, very few cases of BU were discovered; putting into question the hypothesis 
that the changing case finding strategy was the reason for the decline in the number of BU cases 
observed. Therefore, also other factors should also be considered. For example, the efficient 
case detection and treatment of cases has led to a significant reduction of the presence of 
patients with poorly attended ulcerative lesions in the communities. This is likely to correspond 
to a reduction in the spread of the bacteria from active ulcers into the environment which may 
play a role in transmission in the endemic settings. If this is indeed the case, early diagnosis and 
treatment may lead to a decrease in incidence. 
 
Our geographical analysis of houses and farms of BU patients identified the banks of the Mbam 
river as a hotspot of BU prevalence in the district. The river is of fundamental importance for 
the daily activities and the life of the communities living or working in the area. It is surrounded 
by plantations, forest and also wet lands, most of them used as farms and it is suspected that in 
particular the river associated wetlands may be relevant for transmission of M. ulcerans. Also 
other studies have identified residence or activities related or close to river systems as a risk 
factor for BU [18]. It is remarkable in this context that the artificial lake created by the damming 
of the Mape river did not emerge as BU hotspot in the geographical analysis.  
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The observed seasonal variation in case numbers has similarities with other studies from Africa 
[29,30]. It has been hypothesized that the seasonal fluctuation is related to the transition from 
the dry to the rainy season and farming activities which appear to be a risk factor for BU disease 
[18]. In a BU endemic area of Northern Australia, a large spike in cases has been observed 
seven to eight months after an exceptionally long and wet rainy season [31]. Flooding may have 
resulted in increased transmission of M. ulcerans infection. Taking an average delay to 
presentation of 2.7 months into account, this suggests that the incubation period is about 4.5 
months. This is in good agreement with a study on BU patients from southern Australia with a 
residential address outside a known BU endemic area [32]. Here a mean incubation period of 
4.5 months has been estimated with a large variation (between 32 days and 264 days). Not only 
the incubation period for BU seems to be highly variable, but also other factors, such as farming 
activities may influence the time when patients with wounds report to the health system[33]. 
Nevertheless, it is tempting to speculate that in Bankim increased transmission during 
September’s rainy season and flooding of the river banks may be responsible for the peak in 
BU cases reporting to the Bankim hospital in March and April of the following year.  
 
Our analysis of the age spectrum of patients showed, that the BU prevalence in children below 
the age of four is very low. At this age, children have a smaller movement radius when 
compared with older children. Sero-epidemiological studies indicate, that younger children are 
less exposed to M. ulcerans than older children [34]. This suggests that the source of infection 
may be located at some distance from the movement radius of children below the age of four.   
 
43.2% of the BU patients had WHO category 3 lesions, indicating substantial treatment delays 
[35,36]. The reasons leading to this delay are ranging from socio-culture reasons to economic 
reasons. Local beliefs which are in particular deeply rooted in rural communities can lead to 
first seek help from traditional healers [37]. A substantial number of patients came from villages 
far away from the Bankim hospital or other health centers and this was found to be a major 
concern for patients and accompanying relatives. 
Patients in the cohort described here, were enrolled over 5 years giving the opportunity to show 
the evolution and the characteristics of the BU disease over time in the area in and around the 
Bankim. Analyzing the cohort, we highlight the importance of a combined approach in which 
active sensitization, a good surveillance and reporting system, reliable diagnosis, good clinical 
practice and a detailed understanding of the needs of the patients, are all important for BU 
control.  
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Tables  
 
Table 1: Laboratory tests results; cross tables of qPCR results versus ZN results and qPCR 
results versus Culture results 
 
Test ZN (+) ZN (-) 
 n (%) n (%) 
qPCR (+) 80 (54.05) 25 (16.89) 
qPCR (-) 19 (20.43) 45 (48.39) 
 Culture (+) Culture (-) 
 n (%) n (%) 
qPCR (+) 45 (30.41) 91 (61.49) 
qPCR (-) 0 (0.00) 26 (27.96) 
 
 
 
Table 2: IS2404 qPCR results related to sex and age group 
 
Age Gender qPCR positive 
qPCR 
negative OR 95% CI 
p-
value 
n % n % 
≤15 years Male 47 81.03 11 18.97 2.639 1.125-6.190 0.0257 
Female 34 61.82 21 81.03 1.0   
>15 years Male 27 41.5 38 63.9 0.401 0.195-0.822 0.0127 
Female 39 58.5 22 36.1 1.0   
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Table 3: clinical presentation of patients related to age and sex 
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Figures 
 
 
 
Figure 1: Average Monthly number of qPCR positive and negative suspected BU cases 
over 5 years. Panel A shows the average monthly incidence of qPCR positive and negative 
suspected BU cases identified between 2010 and 2014. Panel B shows the total number of 
suspected BU cases and the number of qPCR plosive cases detected per year over the same 
period. 
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Figure 2: Houses and farms of qPCR positive BU cases from 2010 to 2014. Houses (in red) 
of 148 qPCR reconfirmed BU patients were mapped (A) and two main clusters of patients were 
identified in the Bankim HD; one between the Mapé Dam and the Mbam river (B) and the other 
in the upstream area of the Mbam river (C). For the patients living in the two clusters, farms (in 
green) were also mapped and are connected to the residence of the corresponding patient (B, 
C).       
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Figure 3: Flooding of the banks of the Mbam river during the rainy season in September.  
 
 
 
Figure 4: Land cover at the banks of the Mbam river. Areas used for agricultural activities 
(A-C) are interrupted by swamps (D). Sand banks emerge when the river waters are low (E).  
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Figure 5: Relative population age adjusted incidence of PCR positive Buruli ulcer in the 
Bankim HD. On the basis of the population age distribution of the general population living in 
the study area and the age distribution of the qPCR positive BU patients, the population adjusted 
prevalence was computed. The prevalence shown is relative to the prevalence of patients aged 
between zero and less than two years. 
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Case Presentation 
On March 7, 2011, an 11-year-old boy from the town of Bankim in the Adamaoua Region of 
Cameroon—a known endemic focus of Buruli ulcer (BU) [1]—was accompanied by his 
father to the district hospital in Bankim. The patient presented with a BU lesion classified as 
Category II, according to the classifications of the World Health Organization (WHO). The 
partially ulcerated plaque lesion, which was approximately 14 x 6 cm in size, had undermined 
edges characteristic of BU (Fig 1A) [2,3]. Following clinical examination and sample 
collection for diagnosis, the patient’s family refused the standard WHO-recommended 
treatment for BU, which consists of daily rifampicin (10 mg/kg orally) and streptomycin 
(15mg/kg intramuscularly) for eight weeks [4], and the patient left the hospital. Wound 
exudates collected from the patient tested positive in the Mycobacterium ulcerans-specific 
IS2404 quantitative polymerase chain reaction (qPCR) assay [5] with threshold cycle (Ct) 
values ranging from 20.0 to 28.6, indicating a high mycobacterial load. Swab exudates were 
also used for the initiation of a M. ulcerans primary culture on Löwenstein-Jensen medium, as 
previously described [6]. After 8.5 weeks of incubation at 30 °C, mycobacterial growth was 
observed, and the cultured mycobacteria were reconfirmed as M. ulcerans by IS2404 colony 
PCR [6]. Whole genome sequencing of the isolate reconfirmed that it belongs to the local 
clonal complex of M. ulcerans [7]. 
 
One week after reporting to the hospital, the patient was visited at the family farm in 
proximity to the Mbam River, south of Bankim. Between the initial consultation and this 
encounter, the patient did not consult with any other health centre or traditional healer. 
However, the father of the patient applied herbal household remedies, derived from the barks 
of two trees, onto the lesion (Fig 2). Using standard tools in botany, the trees from which the 
herbal remedies were obtained could be identified as Erythrophleum suaveolens [(Guill. & 
Perr.), Brenan] and Stemonocoleus micranthus [8]. The application of the household remedies 
involved the washing of the lesion (at least once per day) with a decoction obtained by boiling 
the bark of E. suaveolens. In addition, a mixture of salt, powdered bark of S. micranthus, and 
the E. suaveolens decoction was applied onto the open lesion daily, over a period of three 
months (Fig 1B). 
 
In May 2013, more than two years after the first encounter, the patient was examined again. 
At this point, the lesion had completely healed and no reduction in movement of the joint was 
observed (Fig 1C). At an additional follow-up visit in January 2014, the scar was found in 
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good condition and no signs of a relapse of the lesion, or the emergence of satellite lesions, 
were observed (Fig 1D, 1E, and 1F). 
Ethical approval to investigate specimens from this patient was obtained from the 
Cameroonian National Ethics Committee (041/CNE/DNM/09 and 172/CNE/SE/2011) and the 
Ethics Committee of Basel (EKBB, reference no. 53/11), and written informed consent was 
obtained from the father of the patient for the publication of the details.  
 
Case Discussion  
The clinical presentation of M. ulcerans disease ranges from non-ulcerative nodules, plaques, 
or oedema to ulcers. The disease often starts as a non-painful nodule or indurated area, which 
may then ulcerate and develop BU-characteristic features, including undermined edges [9]. 
Large ulcerative lesions at joints, like the one described here, often take a particularly long 
time to heal completely and are often associated with long-term complications, such as 
disabilities in the form of contractures or limitations in movement. These long-term sequelae 
of BU may occur even if the patient receives the recommended antibiotic treatment and 
regular wound care [10]. Furthermore, patients with large lesions require physiotherapy and 
rehabilitation in addition to the antibiotic treatment and wound care [11,12]. 
It has been reported from various BU-endemic areas that some patients initially consult 
traditional healers before seeking modern medical treatments [13]. Such consultations with 
traditional healers may lead to a worsening of the lesions, which would, in turn, require 
prolonged wound-care treatment, lead to a delay in healing, and increase the possibility of 
long-term disabilities [14–16]. 
The BU patient presented here did not receive any therapeutic intervention, such as antibiotic 
treatment, surgery, or thermotherapy; instead, his father placed household remedies from the 
barks of two trees, E. suaveolens and S. micranthus, onto the lesion. Medicinal properties of 
the products of these two plants have been previously described, and it is known that they are 
used in traditional medicine in West and Central Africa to treat different conditions, ranging 
from fertility problems to stomach disorders. Interestingly, the bark of E. suaveolens has been 
reported to be used in traditional medicine to treat BU in Côte d’Ivoire and Benin [17–20]. In 
in vitro analyses, extracts from these plants have been shown to have anti-inflammatory and 
antibacterial properties; an ethanol extract from the bark of E. suaveolens has been 
specifically tested for activity against M. ulcerans [21–25]. Since spontaneous healing of BU 
cases has been reported [26], it is not firmly established that the healing of the lesion of the 
patient presented here was supported by herbal remedies. It is possible that the immune 
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responses of the patient could have cleared the infection, even without the application of 
household remedies. In addition, the daily washing and dressing of the wound described here, 
which is similar to the wound care performed in biomedical health care facilities, could have 
facilitated the healing of the wound. The effect of other aspects of care provided to this patient 
by the family, such as feeding, psychosocial support, and the encouragement of the patient to 
continuously move the arm to prevent any disability, may also have contributed to the 
complete healing of the lesion without any long-term sequelae. 
However, the fact that this laboratory-confirmed BU lesion healed completely—after only 
receiving household remedies obtained from the trees E. suaveolens and S. micranthus—may 
merit further research on potential anti-mycobacterial activities of compounds contained in 
the bark of these two trees.  
The combination of rifampicin with streptomycin or clarithromycin, given for eight weeks, is 
a well-established first-line therapy for all forms of active BU disease. While the search for 
next-generation antibiotics against mycobacteria is ongoing, efforts in the endemic areas must 
ensure that cases of BU are discovered early and that patients receive the WHO-recommended 
antibiotic treatment and professional wound management as early as possible. 
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Learning Points 
 The combination of rifampicin with streptomycin or clarithromycin, given for eight 
weeks, is a well-established first-line therapy for all forms of active M. ulcerans disease. 
 In African Buruli ulcer endemic areas, herbal remedies nevertheless continue to be 
applied to lesions of Buruli ulcer patients. 
 Details of possible anti-mycobacterial activities of herbal remedies—obtained from plants 
that are repeatedly reported to be applied to Buruli ulcer lesions in several endemic 
countries in West Africa—may be worth further investigation. 
 Given the possibility of spontaneous remission, the potential contribution of herbal 
remedies to the healing of Buruli ulcer lesions remains to be critically assessed. 
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Figures 
 
  
 
 
Figure 1: Clinical evolution of the Buruli ulcer lesion to which household remedies were 
applied. (A) Untreated, laboratory-reconfirmed Buruli ulcer lesion of a patient who presented 
to the district hospital in Bankim, Cameroon, in early March, 2011. (B) Appearance of the 
lesion one week later, with household remedies applied. (C) Completely closed lesion, two 
years later (September 2013). (D, E, and F) Follow-up pictures of the patient taken in January 
2014, at which time no reduction in movement of the joint was observed and the patient could 
completely flex (E) and extend (F) the elbow. 
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Figure 2: Sources of the herbal products that were used as household remedies and 
applied to the laboratory-confirmed Buruli ulcer lesion. Erythrophleum suaveolens tree 
(A) and sampling of its bark (B). Stemonocoleus micranthus tree (C) and powdered bark (D).  
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Abstract 
Background: While traditionally surgery has dominated the clinical management of Buruli 
ulcer (BU), the introduction of the combination chemotherapy with oral rifampicin and 
intramuscular streptomycin greatly improved treatment and reduced recurrence rates. 
However management of the often extensive lesions after successful specific therapy has 
remained a challenge, in particular in rural areas of the African countries which carry the 
highest burden of disease. For reasons not fully understood, wound healing is delayed in a 
proportion of antibiotic treated BU patients. Therefore, we have performed 
immunohistochemical investigations to identify markers which may be suitable to monitor 
wound healing progression.  
Methodology/Principal findings: Tissue specimens from eight BU patients with plaque 
lesions collected before, during and after chemotherapy were analyzed by 
immunohistochemistry for the presence of a set of markers associated with connective tissue 
neo-formation, tissue remodeling and epidermal activation. Several target proteins turned out 
to be suitable to monitor wound healing. While α-smooth muscle actin positive 
myofibroblasts were not found in untreated lesions, they emerged during the healing process. 
These cells produced abundant extracellular matrix proteins, such as pro-collagen 1 and 
tenascin and were found in fibronectin rich areas. After antibiotic treatment many cells, 
including myofibroblasts, revealed an activated phenotype as they showed ribosomal protein 
S6 phosphorylation, a marker for translation initiation. In addition, healing wounds revealed 
dermal tissue remodeling by apoptosis, and showed increased cytokeratin 16 expression in the 
epidermis. 
Conclusion/Significance: We have identified a set of markers that allow monitoring wound 
healing in antibiotic treated BU lesions by immunohistochemistry. Studies with this marker 
panel may help to better understand disturbances responsible for wound healing delays 
observed in some BU patients. 
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Author summary 
Coagulative tissue necrosis and local immunosuppression caused by the M. ulcerans 
macrolide toxin mycolactone are typical features of Buruli ulcer disease (BU). In particular in 
BU endemic remote rural areas of West Africa, patients often report with large ulcerated 
lesions. Despite the availability of an effective dual antimycobacterial antibiotic therapy, 
some ulcerative lesions may take long time to healing and represent a major burden for the 
patients as well as for the health system. Proper wound healing is a well-orchestrated process 
involving numerous cellular and acellular components. Here we have performed 
immunohistochemical studies with tissue from BU lesions collected before, during and after 
antibiotic treatment. 
We identified a set of markers which are appropriate to evaluate formation of granulation 
tissue (alpha-smooth muscle positive fibroblasts), matrix deposition (pro-collagen 1, 
fibronectin and tenascin C), cell activation (phosphorylated S6), hyper proliferation of the 
epidermis (cytokeratin 16) and apoptosis (cleaved caspase 3) during wound healing. These 
markers may become suitable for assessing progression of tissue repair and for investigating 
the functional basis of impaired wound healing. 
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Introduction 
Buruli ulcer (BU) is a necrotizing skin disease caused by M. ulcerans. It is primarily affecting 
the subcutaneous tissue and can, if untreated, lead to extensive tissue destruction and 
ulceration. The disease has been reported from more than 30 mainly tropical countries [1] 
around the world with the highest incidence in West Africa. The distribution of the disease is 
very focal and typically associated with rural wetlands in close proximity to stagnant or slow 
flowing water bodies [1,2]. The mode of transmission and the environmental reservoir of M. 
ulcerans are still not fully characterized. 
The disease can affect all age groups, but the highest incidence is in children aged between 5 
and 15 years and in the elderly [3,4]. Most of the lesions occur on the limbs, but all parts of 
the body can be affected. The currently recommended treatment consists of daily 
administration of oral rifampicin (10 mg/kg) and intramuscular streptomycin (15 mg/kg) for 8 
weeks under regular supervision. 
BU presents with a variety of clinical forms including nodules, plaques, edema and ulcers and 
in more severe cases multiple lesions as well as osteomyelitis have been observed. The 
disease often starts as a painless swelling or an area of induration which eventually may 
develop the characteristic features of BU such as large ulcers with undermined edges [5]. In 
particular in remote areas of Africa, patients tend to report late to the treatment centers and 
therefore often with very extensive and severe lesions. Long recovery periods are common 
and in the case of large lesions skin transplantation is required and permanent morbidities 
including functional limitations may be observed [6]. While mycolactone causes massive 
local immune suppression in active BU lesions, vigorous local immune responses are 
observed during anti-mycobacterial chemotherapy [7]. Paradoxical reactions including the 
enlargement of ulcers, progression of non-ulcerated plaques and edemas to ulcerative lesions, 
and the emergence of new lesions are frequently observed during chemotherapy [8,9]. 
However, neither ulceration of plaques [10] nor the appearance of new lesions [11,12] is 
necessarily an indicator of a failure of chemotherapy. While many BU lesions tend to heal fast 
after completion of anti-mycobacterial treatment in some patients, the healing process is 
severely delayed in others. Massive infiltration of lesions and the development of atopic 
lymphoid tissue are usually not interfering with wound healing. Vigorous local immune 
responses are thus a good marker of the success of anti-mycobacterial treatment [7], but not 
necessarily associated with complications. In patients being treated for BU, it is therefore 
difficult to differentiate between deterioration resulting from a local immune reconstitution 
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inflammatory syndrome [13] and deterioration resulting from other causes, such as disturbed 
orchestration of wound healing processes or secondary infections. 
Wound healing is a complex process [14], consisting of a sequence of four overlapping and 
integrated phases: rapid homeostasis, inflammation, proliferation and tissue remodeling 
[15,16] which are characterized by inter- and intra-cellular level changes. Once the vascular 
constriction and the fibrin clot are in place, inflammatory cells migrate into the wound bed 
and promote the inflammatory phase characterized by the infiltration of macrophages, 
lymphocytes and neutrophils which clean the wound area, release cytokines to induce 
inflammation and to stimulate fibroblasts, keratinocytes and other elements involved in the 
subsequent phase of the wound healing process [17]. The inflammatory phase is in general 
followed, but partly also overlapping, with the proliferative phase. The proliferative phase is 
characterized by epithelial proliferation and migration through a “temporal” extracellular 
matrix (ECM) composed of several proteins including fibronectin, tenascin and pro-collagen 
I. This matrix acts as support for the fibroblast migration into the wound bed. Fibroblasts and 
endothelial cells are abundant at this time and they support capillary growth and formation of 
granulation tissue. Myofibroblasts, which are specialized fibroblasts, are the main producers 
of collagen in healing wounds. Initially type III collagen is produced and then replaced by 
type I collagen [18–20]. Myofibroblasts can contract by using a smooth muscle type actin-
myosin complex, rich in α-smooth muscle actin (αSMA) and are involved in the contraction 
and closure of wounds [21,22]. αSMA is commonly used as a marker for the detection of 
myofibroblasts, but it is also present in pericytes located at the wall of blood vessels. After 
healing is complete, myofibroblasts are normally eliminated by apoptosis and in healthy tissue 
they are present only sub-epithelially in mucosal surfaces [15]. However, myofibroblasts 
seem to persist in wound granulation tissue that fails to resolve after healing, which is 
considered to be the cause of excessive matrix deposition in hypertrophic scars [15,23]. The 
final remodeling phase of wound healing is also characterized by a reduction in the number of 
newly formed vessels and a slow return to conditions similar to healthy skin tissue [15]. Here 
we have analyzed markers of cell activation, myofibroblast formation and matrix deposition 
in tissue biopsies from BU lesions before, during and after treatment. 
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Materials and Methods 
Ethics statement 
Ethical approval (clearance N⁰ 011, 12/10/2010) for the analysis of the clinical specimens was 
obtained from the provisional national ethical review board of the Ministry of Health Benin, 
registered under the N⁰ IRB00006860. Tissue samples were taken for detailed 
immunohistological analysis, after written informed consent has been given by the patients or 
their guardians.  
 
Study participants 
Eight patients from a highly endemic region of Benin (Ze commune in the Atlantique 
department) with laboratory confirmed BU plaque lesions which reported to the Centre de 
Depistage et de Traitement de l’ulcere de Buruli d’Allada, between April and August 2009 
were included in the study. For all eight patients, biopsies and material obtained during 
wound debridement or excisions were available. Samples were taken at 3 different time 
points: T1 before the start of antibiotic treatment (day-2 to 0), T2 during antibiotic treatment 
(day 26-34) and T3 after the completion of antibiotic treatment (day 56-72). The age of 
patients ranged from five to 70 years and lesions were mostly (5/8) present at the lower 
extremities (Table 1). Clinical diagnosis of BU was reconfirmed at least with 2 of 3 laboratory 
tests applied (ZN staining, IS 2404 PCR and histopathology). All patients tested negative for 
HIV, completed the eight weeks of antibiotic treatment as recommended by the WHO and 
lesions were closed and healed for all patients by day 127 after completion of therapy [10]. 
 
Tissue processing and staining  
Punch biopsies and tissue samples removed during surgical procedures were transferred to a 
10% neutral buffered formalin solution for 24 hours. Afterwards samples were stored and 
transported in 70% ethanol, embedded into paraffin and cut into 5 µm sections with a 
microtome. Sections were recovered on glass slides and after deparaffinization stained with 
Haematoxylin/Eosin (HE) to obtain an overview of the tissue structure and with Ziehl-
Neelsen (ZN) to detect acid-fast bacilli. 
For immunohistochemical and immunofluorescence analysis tissue samples were stained with 
the antibodies and protocols listed in Table 2. For immunohistochemical staining the ABC 
and the NovaRED Kits from Vector laboratories were used and sections were counterstained 
with Haematoxylin. Immunofluorescence staining was performed by using secondary 
Chapter 6. Results 
 
92 
 
antibodies coupled to Alexa fluor 488 or Alexa fluor 594 and sections were counterstained 
with DAPI. 
 
Histopathological features of tissue biopsies  
The tissue biopsies analyzed here for wound healing markers have been analyzed previously 
for the development of inflammatory infiltrates [10]. Shortly, before start of treatment (T1), 
the plaque lesions presented with an intact epidermis and dermis with relatively intact 
collagen and minor infiltration around glands and vessels. The subcutis appeared necrotic and 
edematous with fat cell ghosts. Samples taken four to five weeks after start of antibiotic 
treatment (T2), showed some infiltration with CD20
+
 B-cells, CD3
+
 T-cells and macrophages 
and early granuloma formation. Large necrotic areas were still present at this stage. After 
completion of antibiotic treatment (T3) large surgically excised tissue specimens comprised 
areas with largely healthy appearance, strongly infiltrated areas and completely necrotic areas 
without infiltration [10]. 
  
Chapter 6. Results 
 
93 
 
Results 
Emergence of αSMA-positive, phospoS6-activated myofibroblasts in antibiotic treated 
BU lesions 
Immunohistochemical staining for αSMA revealed staining of blood vessel walls in the 
dermal tissue in all eight tissue samples from BU plaque lesions collected prior to antibiotic 
treatment (T1) (Fig. 1 A2, B2, C2). In contrast, no staining of blood vessel walls was 
observed in the necrotic subcutaneous areas of 7/8 lesions (Fig. 1: A3, B3). Only 1/8 lesions 
(Fig. 1 C3) showed also blood vessel staining in the subcutaneous tissue before 
commencement of therapy. During treatment (T2) no change of the αSMA staining pattern 
was observed in 6/8 lesions, compared to T1. However, in 2/8 lesions, small numbers of 
myofibroblasts were already present at this time point in the dermis and subcutis (data not 
shown). After completion of antibiotic treatment (T3) an increase in αSMA staining was 
observed in 7/8 patients. Extensive blood vessel staining was now also found in the 
subcutaneous tissue, indicative for the development of new blood vessels in the previously 
damaged tissue areas. In addition, in 7/8 lesions αSMA-positive myofibroblasts were found in 
the subcutaneous tissue in association with other infiltrating cells (Fig. 1A6, B6, C6). 
Notably, myofibroblast-rich subcutaneous areas contained numerous cells, which showed 
phosphorylation of the S6 ribosomal protein (Fig. 2A, 2B), a well-established marker for 
downstream effects of mTor signaling. This prompted us to investigate whether S6 is 
activated in myofibroblasts of healing BU lesions. Double staining with antibodies specific 
for αSMA and the Serine235/236 phosphorylated version of the S6 protein were performed on 
the seven myofibroblast-containing BU tissue samples collected after completion of antibiotic 
treatment (T3). αSMA-positive fibroblasts revealed Phospho-S6235/236 staining, which 
indicates that the mTor pathway is activated in the myofibroblasts emerging in antibiotic 
treated BU lesions (Fig. 2). 
 
The ECM proteins tenascin, fibronectin and pro-collagen 1 are expressed in healing BU 
lesions 
Besides αSMA also the expression and distribution of the ECM proteins tenascin, fibronectin 
and pro-collagen 1 turned out to reflect progression to wound healing (Fig. 3). In tissue 
samples from untreated BU patients (T1), only weak cellular and/or subcellular staining of 
fibronectin and tenascin was observed primarily in the dermal region (Fig. 3 A2, A3). The 
amount of these proteins increased after completion of therapy (T3) in all eight patients, as 
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shown in Fig. 3 for two typical patient samples (B and C). The increase in these two proteins 
was most evident in subcutaneous areas, where also the αSMA-positive myofibroblasts 
emerged. 
Before treatment (T1) only few cells, primarily located in the dermal tissue layer, expressed 
pro-collagen 1 (Fig 3 A4). After treatment (T3) substantial numbers of pro-collagen 1-positive 
cells were detected all over the tissue specimen (Fig. 3 B4, C4). These were particularly 
abundant in areas where αSMA-positive myofibroblasts were present (Fig. 3 B1, B2), 
suggesting that myofibroblasts are a major source of newly synthesized pro-collagen 1 in 
healing BU lesions. 
 
Enhancement of cytokeratin 16 expression in keratinocytes early after commencement 
of BU treatment 
Cytokeratin (CK16) expression in the epidermis is a marker for keratinocyte hyper-
proliferation [24], as found associated with wound healing. It is not present in healthy 
epidermal skin (Fig. 4 A1). Epidermal hyper proliferation is a characteristic feature in BU 
lesions, and in 4/8 lesions collected prior to treatment some CK16 staining of keratinocytes 
was observed (Fig. 4 A2). CK16 staining increased in intensity and extension during (Fig. 4 
A3) and in particular after completion of antibiotic treatment (Fig 4 A4). Along with this, 
epidermal hyperplasia was also more pronounced after therapy in 7/8 patients. Another 
characteristic observed for CK16 was the heterogeneity of the intensity of staining within 
individual specimen (Fig. 4B, Region1, Region 2), which may reflect diversity in keratinocyte 
activation in different areas of BU lesions. 
 
Emergence of apoptotic fat cells after therapy may reflect tissue remodeling 
Caspase 3 is a main effector caspase of the apoptotic cascade and antibodies specific for 
neoantigens of cleaved caspase 3 (CC3) are a useful tool to identify apoptotic cells in paraffin 
embedded tissue. For all BU lesions we observed a decrease of CC3-positive cells during 
treatment (T2) and an increase after therapy (T3) (Fig. 5). Before commencement of antibiotic 
therapy CC3-positive cells were observed in very small numbers in infiltrated areas of intact 
dermal tissue and around remaining blood vessels (Fig. 5A). The necrotic areas were devoid 
of CC3-positive cells, but contained abundant numbers of fat cell ghosts, which may have 
already gone through apoptosis (Fig. 5B). During treatment CC3-positive cells were only very 
rarely observed in the dermal and subcutaneous layer (Fig. 5C, D). After completion of 
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treatment some of the infiltrating immune cells were CC3-positive (Fig. 5E), which may 
reflect physiological elimination of inflammatory cells. Notably, 6/8 patients revealed strong 
CC3 staining of fat cells far away from the necrotic core (Fig. 5F), which suggests that 
apoptosis of fat cells may be an element of tissue remodeling in healing BU lesions. 
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Discussion 
Specific treatment of BU is highly effective since the introduction of the R/S antibiotic 
combination therapy in 2004 and recurrence rates could be reduced [8]. Beside this promising 
development wound healing and wound management is still a major problem in the remote 
rural BU endemic areas of Africa where patients tend to present late to hospitals [25]. While 
the mycobacteria may be efficiently eliminated by the specific treatment, large open wounds 
may persist and often prolonged wound care and skin grafting are necessary [26,27]. Why 
some BU lesions heal very fast while others require a long time till complete healing, is 
unclear and not related to the size or lesion type. Paradoxical reactions may be caused by 
secondary bacterial infections [28], immune reconstitution inflammatory syndrome like 
mechanisms [11,13,29,30] or inappropriate cell activation and disturbed transition from the 
inflammatory to the healing phase. For future characterization of mechanisms causing wound 
healing delays, we have studied here the emergence and spatial distribution of wound healing 
markers in healing BU lesions. 
Important key players during wound healing are αSMA-positive myofibroblasts. While in 
healthy skin αSMA is typically present only in cells located at the walls of blood vessels and 
in skin adnexa, it is also produced in healing wounds by myofibroblasts, a highly specialized 
cell type involved in granulation tissue formation, production of ECM proteins, and wound 
contraction [23]. After completion of antibiotic treatment we observed these specialized 
fibroblasts in substantial numbers in regenerating BU lesions. Minimal presence of 
myofibroblasts during the treatment phase (T2) is probably related to the massive 
mycolactone mediated tissue necrosis which delays granulation tissue formation.  
Further analysis revealed that these myofibroblasts were activated via the intracellular 
regulatory mTor pathway, which mediates cellular events critical in cell proliferation, 
movement and metabolism [31,32]. In mice PI3K-Akt activation promotes cutaneous wound 
repair and an elevated mTor activity strongly accelerates wound healing [33]. 
Therefore it is speculated that activation of this pathway in humans might help to treat large, 
chronic and life threatening wounds and accelerate wound healing [34]. Antibodies binding to 
the phosphorylated S6 protein can be used to determine whether cells show an activation of 
the mTor pathway [32,35]. Here we observed that, after treatment of BU lesions, many cells, 
most notably αSMA-positive myofibroblasts, exhibited increased S6 phosphorylation, 
indicating enhanced protein synthesis and/or proliferation. In contrast, phosphorylated S6 
protein positive cells are barely detectable in healthy skin [36]. 
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Malnutrition or starvation is known to repress mTor activation (most likely via Insulin/IGF 
deficiency) [35] and may contribute to impaired wound healing in some BU patients. Based 
on these results, we will investigate in a next step whether mTor pathway activation can help 
to discriminate between healing and non-healing wounds in BU.  
Activated myofibroblasts are not only involved in wound contraction but they also produce 
the ECM proteins fibronectin, tenascin and different pro-collagens. Together with newly 
formed blood vessels and inflammatory cells they built the granulation tissue, which is a 
prerequisite for successful healing of dermal injuries [15]. In healthy skin, fibronectin is found 
in blood vessels, in dermal/epidermal junctions and in hair follicles [17,20]. In contrast 
tenascin-C and pro-collagen 1, which is the zymogen of collagen 1, are almost absent in the 
healthy skin but are abundant in healing skin lesions [37–39]. The presence of activated 
myofibroblasts and deposition of ECM proteins in response to BU specific therapy is a strong 
indication for a successful ongoing wound healing process. We observed the formation of 
granulation tissue in all 8 patients after completion of therapy and in 2/8 patients already at 
time point T2 during chemotherapy. Indeed all BU lesions analyzed in this study, showed a 
good clinical outcome, no recurrences were observed and patients could be discharged from 
the hospital 42 to 127 days after completion of therapy [10]. 
Although, the epidermis and dermis of plaque  lesions may stay closed and intact for a long 
time [10], the expression of CK16 is a clear indication that also the epidermis is affected in 
BU lesion. CK16 is a marker of epidermal hyper-proliferation and is expressed by activated 
keratinocytes in wounded tissue [24]. In antibiotic treated BU lesions we observed an increase 
of CK16 expression over time. Absence or only faint CK16 staining in tissue taken before 
therapy, support the idea that the cytotoxic and immunosuppressive effects of mycolactone, 
which arrests the lesions in a chronic wound healing state and also suppresses keratinocyte 
activation. Heterogeneous staining of the epidermal layer in larger surgical excisions excised 
at time point T3 may reflect disease activity in the underlying tissue. Augmented epidermal 
CK16 expression is also characteristic for inflammatory skin diseases with a hyper-
proliferative epidermis, such as psoriasis, and CK16 is used as marker to evaluate the efficacy 
of anti-psoriatic treatments [40]. In addition, intra-dermal injection of the pro-inflammatory 
cytokine interferon-gamma has been shown to increase epidermal CK16 expression [41]. 
Therefore, enhanced CK16 expression in BU lesions after treatment is likely the consequence 
of increased dermal inflammation in response to successful antibiotic treatment and 
mycolactone clearing. 
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Each phase of the complex wound healing process is characterized by the presence of a 
specific population of cells producing specific proteins and fulfilling specific tasks. Tissue 
remodeling by controlled cell death (apoptosis) is as important as proliferation. If cell death is 
wrongly regulated and certain cells persist after their task is accomplished this may lead to 
wound healing complications, like the development of hypertrophic scars or keloids [23,42]. 
Additionally, infiltrating inflammatory cells need to be removed after the wounded area has 
been cleaned. 
Here we used CC3 as an established marker which is detectable in a small time window in 
end-stage apoptotic cells. Its short duration of expression explains the small number of 
positive cells in our BU lesions. It is known that mycolactone induces apoptosis in vitro and 
in vivo leaving behind only necrotic tissue devoid of any surviving cells [43,44]. Accordingly, 
at time point T1, subcutaneous tissue presented nearly devoid of any intact cell, except for 
some remaining cells around blood vessels and CC3 positive cells were very rare. While a 
further decrease of CC3 staining was observed during antibiotic treatment (T2), after 
treatment (T3) CC3 staining became prominent in the granulation tissue and was even more 
pronounced in nearby fat tissue. At this stage the wound healing process is in a state between 
the inflammatory and the remodeling phase. The inflammatory phase sets in shortly after the 
start of treatment and is characterized by a strong mixed infiltration, presence of granulomas 
and giant cells as well as B-cell cluster [30]. Apoptosis of inflammatory cells observed in the 
temporary granulation tissue at time point T3 is a necessary step in order to form healthy new 
tissue [15]. No apoptotic myofibroblasts were detected, since they are still needed at this stage 
of the wound healing process. The observed emergence of apoptotic fat cells may also be a 
result of the ongoing tissue remodeling process and reflect the removal of superfluous or 
impaired fat tissue. In conclusion this study shows that markers like αSMA, fibronectin, pro-
collagen 1, tenascin-C and CK16, are suitable to monitor healing of BU lesions. The present 
study also suggests that the mTor pathway might play an important role during wound healing 
in BU. Further investigations using the presented marker set to compare healing and non-
healing BU lesions may help to clarify steps and aspects of this complex process. Whether 
wound healing deficiencies are associated with insufficient activation of the mTor pathway 
needs to be examined in a larger cohort. 
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Figure 
 
Figure 1: Emergence of αSMA-positive myofibroblasts in antibiotic treated BU lesions 
Histological sections were stained with an anti-αSMA antibody and counterstained with 
Haematoxylin. Typical results with tissue specimens of three BU patients (A, B and C) are 
shown. Specimens were taken before or after completion of antibiotic therapy. A1, B1, C1: 
scans of the stained punch biopsies taken before commencement of antibiotic therapy. A2, 
B2, C2: higher magnification showing that αSMA staining in the dermis before treatment is 
restricted to blood vessels. A3, B3, C3: Higher magnification of the subcutaneous tissue 
showing blood vessel staining in only 1/8 patients (C3) and no specific staining in the other 
patients (A3, B3). A4, B4, C4: scans of the tissue excised after completion of antibiotic 
treatment. A5, B5, C5: αSMA-positive blood vessels were found in the dermis of all patients. 
A6, B6, C6: large numbers of αSMA positive myofibroblasts were found in strongly 
vascularized subcutaneous areas after completion of therapy. 
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Figure 2: αSMA-positive myofibroblasts in antibiotic treated BU lesions show 
phosphorylation of the S6 ribosomal protein 
Histological sections were stained either by immunohistochemistry and counterstained with 
Haematoxylin (A, B) or by immunofluorescence double staining (C-G) and DAPI 
counterstaining of nuclei (C). αSMA staining (A) and Phospho-S6235/236 staining (B) were 
found in the same tissue areas. Immunofluorescence staining for αSMA (D) and Phospho-
S6
235/236 
(E) revealed co-staining of cells with fibroblast morphology (F, G), demonstrating 
that the mTor pathway is activated in the myofibroblasts emerging in antibiotic treated BU 
lesions. 
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Figure 3: Increased expression of the ECM proteins tenascin, fibronectin and pro-
collagen 1 in healing BU lesions 
Serial histological sections were stained with antibodies against αSMA and the ECM proteins 
tenascin, fibronectin and pro-collagen 1 and counterstained with Haematoxylin. Panel A 
represents a typical lesion before commencement of antibiotic therapy (T1) and Panel B and 
C typical tissue specimens from two patients after completion of therapy (T3). Whereas no or 
only weak staining for αSMA, tenascin, fibronectin and pro-collagen 1 was observed before 
therapy (A1-A4), tissues turned strongly positive for all four markers after completion of 
treatment (B1-B4 and C1-C4). Staining of ECM proteins was most prominent in areas 
containing many αSMA positive myofibroblasts. 
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Figure 4: Increase of Cytokeratin 16 expression by keratinocytes during antibiotic 
therapy 
Histological sections were stained by immunohistochemistry with an anti-Cytokeratin 16 
antibodies and were counterstained with Haematoxylin. While healthy skin was completely 
devoid of Cytokeratin 16 staining (A1), some staining was observed (A2) in the epidermal 
layer of untreated BU lesions (T1). Staining intensity and epidermal thickness increased in 
samples collected during (T2) and after completion (T3) of antibiotic therapy (A3, A4). After 
completion of therapy (T3) heterogeneous staining (B, Overview), with some areas of the 
epidermal layer showing much weaker Cytokeratin 16 staining (Region 1) than others 
(Region 2) was observed.  
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Figure 5: Emergence of apoptotic fat cells after completion of antibiotic therapy 
Histological sections were stained by immunohistochemistry with anti-CC3 antibodies and 
were counterstained with Haematoxylin. Infiltrated necrotic areas (A, C, E) and fat cell layers 
(B, D, F) of the subcutaneous tissues are displayed.  Before treatment some of the infiltrating 
cells showed CC3 staining (A). No staining was observed in the subcutaneous layer (B). 
During treatment (C, D) only very few cells showed CC3 staining. After treatment substantial 
numbers of infiltrating cells were CC3-positive (E) and in addition larger numbers of CC3-
positive fat cells were found (F). 
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Abstract 
Background Keloids and hypertrophic scars are caused by excessive cutaneous wound healing 
that is characterized by myofibroblast persistence and extracellular matrix accumulation. 
mTOR has been shown to be activated in keloids, and dual TORC1/2 inhibitors were reported 
to display more potent anti-fibrotic effects in keloid organ cultures than the more selective 
TORC1 inhibitor rapamycin. 
Objectives To analyse the in vivo status of TORC1 and TORC2 signalling in normal scars, 
hypertrophic scars and keloids. To investigate if increased mTOR signalling is specific for 
myofibroblast. 
Methods Formaldehyde fixed and paraffin embedded biopsies were investigated by 
immunostaining for ribosomal protein S6 phosphorylation (marker for TORC1 signalling), 
AKT(S473) phosphorylation (marker for TORC2 signalling), and α-smooth muscle actin 
(marker for myofibroblasts).  
Results None of the investigated scar and keloid biopsies revealed detectable levels of 
AKT(S473) phosphorylation in fibroblasts. However, all hypertrophic scars and keloids 
revealed strongly increased S6 phosphorylation, which was prominent both in myofibroblasts 
and in α-smooth muscle actin negative connective tissue cells. 
Conclusions Persistent signalling via mTOR complex 1 rather than mTOR complex 2 drives 
extracellular matrix over-production in hypertrophic scars and keloids. 
 
 
What is already known about this topic? 
 mTOR is activated in keloids, which are cutaneous overgrowths that display excessive 
extracellular matrix deposition by myofibroblasts. 
 Both mTOR complex 1 and mTOR complex 2 signalling is thought to be required to 
drive fibrosis in keloid organ cultures. 
What does this study add? 
 Biopsies from hypertrophic scars and keloids revealed strongly increased signalling of 
mTOR complex 1, but not of mTOR complex 2. 
 Increased mTOR complex 1 signalling in excessive scars was most prominent in 
fibroblasts, but not restricted to myofibroblasts. 
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Introduction 
Hypertrophic scars and keloids are fibrous overgrowths, which may develop in response to 
skin injury, but spontaneous forms also exist. It has been reported that tissue extracts from 
keloids contain elevated levels of activated mTOR (mammalian target of rapamycin) and the 
downstream mTOR signalling component p70KDa S6 kinase (p70S6K)1. mTOR is a 
serin/threonine kinase which is involved in the regulation of fundamental cellular processes, 
such as growth, proliferation, protein synthesis and autophagy, and has emerged as an 
important target for the treatment of certain cancers and inflammatory diseases2. mTOR is 
part of two distinct cellular signalling complexes: mTOR complex 1 (TORC1) and mTOR 
complex 2 (TORC2). These complexes are differentially regulated and drive diverse cellular 
activities3. Blockade of mTOR specifically impaired expression of collagen biosynthesis 
genes in fibroblasts from hypertrophic scars and keloids4. mTOR inhibitors also showed 
strong anti-fibrotic activity in keloid organ cultures5, which revealed increased TORC1 and 
TORC2 signalling in fibroblasts6. Consequently, dual TORC1/2 inhibitors displayed more 
potent effects in keloid organ cultures than the more selective TORC1 inhibitor rapamycin5,6. 
However, organ cultures and cell cultures may differ from the in vivo situation in various 
aspects. mTOR signalling may become up-regulated in response to tissue injury during biopsy 
excision, because the mTOR pathway has been found to be activated in connective tissue cells 
of wound granulation tissue7. In addition, the used organ and cell culture media contain high 
levels of amino acids and insulin, factors which are known to activate mTOR signalling8. 
Therefore, we performed immunostaining analyses on immediately fixed biopsies to compare 
the in vivo status of mTOR activity in normal scars, hypertrophic scars and keloids. To 
visualize TORC1 signalling we investigated S6 phosphorylation, which is an established 
downstream marker of TORC1 pathway activation9 and involved in translation initiation10. 
mTOR signalling activates p70S6 kinase which phosphorylates Ser235, Ser236, Ser240 and 
Ser244 of S611. However, S6(Ser235) and S6(Ser236) may also be phosphorylated via the 
RAS/ERK pathway12. Therefore, we used two different anti-pS6 antibodies, which detect 
specifically S6(Ser235/236) or S6(Ser240) phosphorylation sites, respectively. To visualize 
TORC2 signalling, we stained for pAKT(S473), a downstream marker of the TORC2 
pathway3. We also performed pS6 and alpha smooth muscle actin (αSMA) 
immunofluorescence double staining to investigate if the mTOR pathway is activated in 
myofibroblasts, a specialized contractile cell type, which plays an important role in wound 
healing and fibrosi13. 
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Material and Methods 
5µm thin paraffin sections of normal scars (n=5), hypertrophic scars (n=4), and keloids (n=6) 
were de-paraffinized and reacted with the following antibodies: Rabbit anti-pS6Ser(235/236) 
(Cell Signalling #2211; 1:400); mouse anti-pS6Ser(240) (DAKO #M7300; 1:100), rabbit anti-
pAKT(S473) antibody (Cell Signaling, #4006; 1:25), and mouse anti-αSMA (Novocastra, 
#NCL-SMA; 1:100). Slides were then staining with Alexa488 and/or Alexa594 labelled 
secondary antibodies (Invitrogen; 1:500) and covered with Prolong Gold/DAPI (Invitrogen) 
mounting medium. The study was approved by the ethical committee of the University of 
Basel (EK.242/13). 
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Results 
Anti-pS6 antibodies showed strong staining in all investigated hypertrophic scars and keloids 
(red in Figure 1, b1-2). In contrast, pS6 positive cells were rare in normal scars (red in 
Figure 1, a1-2). The vast majority of pS6 positive cells demonstrated fibroblast morphology 
(Figure 1, b2). While pS6 positive myofibroblasts were barely detectable in normal scars 
(Figure 1, a1-2), a subset of pS6 positive cells in hypertrophic scars and keloids stained also 
positive for the myofibroblast marker αSMA (green in Figure 1, b1-2). Double staining with 
antibodies specific for S6Ser(235/236) phosphorylation (red in Figure 1, c1 and c3)  and 
S6Ser(240) phosphorylation (green in Figure 1, c2 and c3) revealed a largely overlapping 
staining pattern (Figure 1, c3), suggesting that S6 phosphorylation is mainly driven by mTOR 
signalling. Surprisingly, pAKT(S473) staining was neither detectable in normal scars (red in 
Figure 2, a1-2), nor in keloid biopsies (red in Figure 2, b1-2). However, the used antibody 
showed strong reactivity with a positive control (human breast cancer xenograft) (red in 
Figure 2, c1-2).  
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Discussion  
These results demonstrated that S6 is strongly activated in hypertrophic scars and keloids in 
vivo, and supports the findings of organ culture experiments that mTOR signalling is 
increased in keloids5,6. We found that the vast majority of keloid fibroblasts exhibited pS6 
staining, but only a subset of them displayed αSMA staining. As such, increased protein 
synthesis in keloids and hypertrophic scars seem not to be restricted to myofibroblasts, 
although this cell type has been suggested to play a key role in fibrotic diseases13.  
Surprisingly, we did not detect expression of the TORC2 signalling marker pAKT(S473) in 
any of the analysed scar biopsies, although enhanced pAKT(S473) staining has been 
demonstrated in keloid organ cultures6. Keloid fibroblasts display enhanced proliferation in 
response to wounding14. Therefore it is tempting to speculate that increased TORC2 
signalling in organ cultures is the result of insult stimuli and subsequent tissue repair 
processes. Matured keloid lesions may contain only a small number of proliferating 
fibroblasts despite sustained matrix protein over-production for a long period of time. This 
may be reflected by high TORC1 and low TORC2 signalling in vivo, because the TORC1 
pathway is important for protein synthesis, whereas dual TORC1/TORC2 signalling seems to 
endow cells with increased proliferative and invasion potential2. TORC2 signalling in non-
malignant cells has been suggested to require continuous stimulation by growth factors, such 
as insulin like growth factor8. Since keloid fibroblasts have been shown to over-express 
insulin like growth factor receptor 115, they may display an increased sensitive to the 
mitogenic activity of insulin present at high concentrations in organ and cell culture media. 
Consequently, keloid organ cultures have only limited value to predict clinical effects of 
mTOR inhibitors. 
In conclusion, we could clearly demonstrate that the TORC1 pathway is strongly activated in 
mature keloids, and TORC1 signalling may thus contribute to persistently elevated protein 
synthesis and extra-cellular matrix deposition in established lesions.  These findings support 
the idea that mTOR inhibitors might provide therapeutic benefit for the treatment of 
hypertrophic scars and keloids. Whether or not, and at which stage of the disease, dual 
TORC1/2 inhibitors may be more effective than TORC1 selective inhibitors needs to be 
tested in clinical studies. 
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Table 1: Details of investigated clinical samples 
 
 
 
 
 
 
 
 
 
 
 
 
  
Chapter 7. Results 
 
116 
 
Figure  
 
 
 
Figure 1: Immunofluorescence staining of phosphorylated S6 and alpha smooth muscle 
actin in normal and keloid scars.  
An overview of S6(Ser235/236) (red) and αSMA (green) staining in a normal scar is shown in 
(a1), and in a keloid in (b1). High magnification images to visualize co-localisation of 
S6(Ser235/236) (red) and αSMA (green) in a normal scar are shown in (a2), and in a keloid in 
(b2). Overview and high magnification images in (a) and (b) are from different patients. The 
images in (C) illustrate double staining of pS6(Ser235/236) (red) and pS6(Ser240) (green) in 
a keloid scar – pS6(Ser235/236) staining (red) is shown in (c1), pS6(Ser240) (green) staining 
in (c2), and the overlay of both stainings in (c3). 
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Figure 2: Immunofluorescence staining of phosphorylated AKT(S473) in a normal scar, 
in a keloid scar, and in a tumour xenograft.  
Examples of normal scars (a), keloid scars (b), and tumour xenograft serving as positive 
control (c) are shown at low magnifications (a1, b1, c1), and at high magnification (a2, b2, 
c2).  Overview and high magnification images in (a) and (b) are from different patients. 
Specific pAKT(S473) immunofluorescence signals were neither detected in normal scars (a), 
nor in keloids (b), whereas the anti-pAKT(S473) antibody revealed very strong immune 
reactivity in paraffin sections of a tumour xenograft (c).  
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Summary 
Background The ribosomal protein S6 (S6) is part of the translation machinery and activated 
by phosphorylation via the mammalian target of rapamycin (mTOR) pathway, which is 
activated in psoriatic skin.  
Objectives To investigate which S6 sites are phosphorylated in psoriasis and atopic dermatitis 
(AD), and to study whether S6 phosphorylation is associated with inflammation and/or 
keratinocyte hyper-proliferation.   
Methods Healthy skin and skin lesions of patients with psoriasis and AD were investigated by 
immunostaining using antibodies which stain proliferating cells, leukocytes, and distinct 
phosphorylated sites of S6. 
Results All psoriasis and AD lesions revealed abnormal S6 phosphorylation in the epidermis. 
Extent of S6 phosphorylation was diverse, generally stronger in psoriasis, and correlated in 
both diseases with inflammation. S6 showed differential phosphorylation in distinct epidermal 
layers, which was most pronounced in hyper-proliferative regions. 
Conclusions Differential S6 phosphorylation may have a role in abnormal keratinocyte 
proliferation/differentiation.  
 
 
What is already known about this topic? 
 Phosphorylation of ribosomal protein S6 (S6) is important for translation initiation.  
 S6 becomes phosphorylated via the mammalian target of rapamycin (mTOR) pathway, 
which is activated in psoriatic skin. 
 
What does this study add? 
 In psoriasis and atopic dermatitis S6 phosphorylation is associated with inflammation 
and epidermal hyper-proliferation.  
 S6 is differentially phosphorylated in distinct layers of the diseased epidermis, which 
may impact keratinocyte proliferation/differentiation 
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Introduction 
Ribosomal protein S6 (S6) is part of the 40S ribosomal subunit of the translation machinery1. 
Phosphorylation of S6 is required for translation initiation and occurs on a cluster of five 
serine residues at the carboxyl terminus of the protein2,3. The mammalian target of rapamycin 
(mTOR) pathway seems to be the predominant regulator of S6 activity. mTOR is a 
serin/threonine kinase that is part of a protein complex involved in the regulation of cell 
growth, proliferation, protein synthesis and autophagy, and has emerged as an important 
target for the treatment of certain cancers and inflammatory diseases. mTOR signalling 
activates S6 kinase which phosphorylates Ser235, Ser236, Ser240 and Ser244 of S6, and 
inhibition of mTOR causes a drastic reduction in S6 activation4. However, Ser235 and Ser236 
can also be phosphorylated via the RAS/ERK pathway5. Ser247 seems to be a target of the 
casein kinase 1 (CK1) family of protein kinases6. 
Psoriasis and atopic dermatitis (AD) are inflammatory skin diseases with different aetiology, 
but often similar clinical appearance due to keratinocyte hyper-proliferation and incomplete 
differentiation of the epidermis. Clinical data suggest that mTOR inhibitors provide 
therapeutic benefit for psoriasis7,8. Moreover, mTOR signalling and S6Ser(235/236) 
phosphorylation was found to be increased in psoriatic skin.9 
We have investigated S6 activation in depth by using antibodies, which detect specifically 
S6Ser(235/236), S6Ser(240/244) or S6Ser(240) phosphorylation sites. To evaluate if S6 
activation is psoriasis specific or a more general characteristic of epidermal inflammation, we 
also analysed AD biopsies. In addition, we investigated, whether S6 phosphorylation is 
associated with inflammation and/or hyper-proliferation. 
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Material and Methods 
The study was approved by the ethical committee of the University Basel (EK.242/13). All 
analysed biopsies were from patients that have not undergone therapy known to affect the 
phosphorylation status of S6. 
5µm thin paraffin sections from lesional (psoriasis n=10; AD n=5) and healthy skin were de-
waxed, heat pre-treated with 0.1m citrate buffer (Ph 6.0) and stained with the following 
antibodies.. Rabbit anti-phospho-S6Ser(235/236) (Cell Signalling #2211; 1:400); rabbit anti-
phospho-S6Ser(240/244) (Cell Signalling #2215; 1:400); mouse anti-phospho-S6Ser(240) 
(DAKO #M7300; 1:100); rabbit anti-Ki67 (DAKO #A0067; 1:200); mouse anti-CD45 
(DAKO M0701; 1:100). Immunofluorescence staining was performed by using secondary 
antibodies coupled to Alexa-fluor488 or Alexa-fluor594 (Invitrogen; 1:500) and mounted 
with Prolong® Gold/DAPI (Invitrogen). 
Control immunostaining experiments with tumour xenografts treated with a selective mTOR 
inhibitor or placebo confirmed that the used phospho-S6 antibodies are highly specific for 
mTOR regulated phosphorylation sites (data not shown). 
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Results 
While healthy human skin revealed detectable S6 activation only in the stratum granulosum 
(Fig.1, a1-3), all investigated psoriatic lesions showed abnormal phosphorylation of S6 in 
supra-basal and differentiating cell layers of the epidermis (Fig.1, a4-6 and a7-9). The 
staining pattern of S6 phosphorylation was diverse amongst patients with psoriasis. While 
some lesions revealed staining in all epidermal cell layers (Fig.1, a4-6), others showed 
staining of individual cells or cell clusters (Fig.1, a7-9). Psoriasis I and II illustrate extreme 
examples of different patients; such differences were generally less pronounced within 
lesions. Abnormal S6 phosphorylation was also observed in all investigated AD samples. The 
staining pattern showed also variation (Fig.2, a1-3 and a4-6), but the extent of S6 activation 
was generally less pronounced.  
Abnormal S6 phosphorylation was associated with inflammation: double 
immunofluorescence staining of phosphorylated S6 and the pan-lymphocyte marker CD45, 
revealed that the extent of S6 phosphorylation was generally much stronger in severely 
inflamed areas than in those containing low numbers of inflammatory cells, both in psoriasis 
(Fig.1, b1 and b2) and in AD (Fig.2, b1 and b2).  
Supra-basal cell layers showing abnormal S6 phosphorylation in inflamed areas contained 
many Ki67 positive keratinocytes (Fig.1, c2), whereas proliferating keratinocytes in basal 
layers were mostly devoid of activated S6. Phosphorylated S6 was not detected in 
proliferating keratinocytes of healthy human epidermis (Fig.1, c1). 
Most notably, antibodies against different phosphorylation sites of S6 exhibited distinct 
staining patterns. This was most evident in strongly inflamed, highly active areas where all 
supra-basal epidermal layers showed S6 activation (Fig.1, a4-6). Such lesions revealed 
S6Ser(240) phosphorylation predominantly in lower epidermal layers (Fig.1, a5 and a6) 
containing many proliferating cells (Fig.1, c2), whereas S6Ser(235/236) phosphorylation was 
found to be also strong in differentiating compartments (Fig.1, a4 and a6). S6 
phosphorylation in basal epidermal cells was rare and restricted to small areas. Weakly 
inflamed areas revealed supra-basal co-phosphorylation of S6Ser(240) and S6Ser(235/236) in 
only a subset of cells, but S6Ser(240) phosphorylation also in differentiating layers of the 
epidermis (Fig.1, a7-9). 
An antibody recognizing both S6Ser(240) and S6Ser(244) phosphorylation also revealed a 
staining pattern which differed from that obtained with the S6Ser(240) selective antibody, and 
indicated stronger S6Ser(244) phosphorylation in differentiating compartments of the hyper-
proliferative epidermis (Fig.1, d1-2). 
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Discussion 
Our findings confirm that the mTOR pathway is activated in psoriatic skin, but do not support 
the conclusion that S6 is predominantly activated in upper epidermal layers9. Buerger et al. 
used S6Ser(235/236) phosphorylation as downstream marker for mTOR activity, but 
phosphorylation of this site may also be stimulated by RAS/ERK signalling5, known to be 
active in psoriasis10. Notably, Wang et al.11 reported increased activated ERK1 
immunostaining in differentiating compartments of the psoriatic epidermis, which suggests 
that RAS/ERK signalling actually contributes to S6Ser(235/236) phosphorylation. 
We found that S6 is differentially phosphorylated in the psoriatic epidermis. The S6Ser(240) 
site is peculiar with respect to its predominant phosphorylation in proliferating compartments 
of highly active lesions. In contrast, weakly inflamed lesions, which showed scattered S6 
phosphorylation in proliferating compartments, revealed S6Ser(240) phosphorylation also in 
differentiating compartments. This may indicate normalization of epidermal differentiation in 
regressing lesions, because S6Ser(240) is phosphorylated in the stratum granulosum of 
healthy skin. Therefore it is tempting to speculate that activation of S6 has a role in terminal 
differentiation of keratinocytes. 
We found increased S6 phosphorylation also in AD, suggesting that mTOR is generally 
activated in inflammatory skin diseases with epidermal hyper-proliferation. Inflammatory 
cells secrete growth factors, such as insulin like growth fator-1 (IGF-1), known to activate the 
mTOR pathway12, and to inhibit keratinocyte differentiation13. Beside this, clinical 
improvement of psoriasis was found to be associated with decreased IGF-1 expression14. 
S6 activation seems to be dispensable for normal keratinocyte proliferation, because S6 
phosphorylation is not evident in dividing keratinocytes of healthy skin. Thus, mTOR 
inhibitors may selectively target pathologically activated keratinocytes, a hypothesis 
supported by the observation that mTOR inhibition suppresses UVB-induced keratinocyte 
hyper-proliferation15, but does not affect normal epidermal turnover.  
mTOR inhibition might help to treat hyper-proliferative skin diseases. Analysis of site 
specific S6 phosphorylation in skin biopsies could be useful to assess pharmacodynamics of 
mTOR inhibitors in clinical trials. Finally, differential phosphorylation of S6 may have 
implications for tumour growth, which should be taken into account when analysing tumour 
samples. 
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Figure  
 
 
  
Figure 1: Immunofluorescence images showing differential S6 phosphorylation, CD45 
expression and Ki67 positive cells in psoriatic lesions. 
In (a) staining of phospho-S6Ser(235/236) is shown in red (a1, a4 and a7) and staining of 
phospho-S6Ser(240) in green (a2, a5 and a8); overlays of both stainings are shown in a3, a6 
and a9. In normal skin (a1-3) S6 phosphorylation was restricted to the stratum granulosum. 
In contrast, psoriatic lesions also revealed S6 phosphorylation in suprabasal cell layers (a4-6 
and a7-9). The staining patter was highly variable between patients as shown by the 
following two examples. Psoriasis lesion I (a4-6): staining of phospho-S6Ser(235/236) (a4) 
was visible in all supra-basal epidermal layers and more prominent in differentiating 
compartments, whereas staining of phospho-S6Ser(240) (a5) was mostly restricted to 
proliferating compartments. Psoriasis lesion II (a7-9): Ser235/236 (a7) and Ser240 (a8) were 
co-phosphorylated in a small subset of supra-basal cells, but showed distinct phosphorylation 
patterns in differentiating layers. Double staining of CD45 (green in b1 and b2) and 
phospho-S6Ser(235/236) (red in b1 and b2) showed S6 phosphorylation in all epidermal 
layers of a strongly inflamed lesion (b1), but restricted S6 phosphorylation in a weakly 
inflamed lesion (b2). Double staining of phospho-S6(Ser240) (green in c2) and Ki67 (red in 
c2) showed that S6 was activated in many proliferating keratinocytes. Most double stained 
cells were located in supra-basal compartments of the psoriatic epidermis (c2), but S6 
activation was not detectable in proliferating keratinocytes of normal skin (c1). Ser240/244 
and Ser240 were also differentially phosphorylated in a highly active psoriatic lesion, where 
Ser240/244 phosphorylation was strong in both supra-basal and differentiating layers (d1), 
whereas Ser240 phosphorylation was mostly restricted to proliferating epidermal layers (d2). 
Scale bars: 50µm. 
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Figure 2: Immunofluorescence images showing differential S6 phosphorylation and 
inflammation in AD lesions. 
S6 phosphorylation patterns found in AD lesions (a1-3 and a4-6). AD lesion I (a1-3): staining 
of phospho-S6Ser(235/236) (red in a1) was most prominent in differentiating compartments, 
whereas staining of phospho-S6Ser(240) (green in a2) was mostly restricted to proliferating 
compartments. AD lesion II (a4-6): staining of phospho-S6Ser(235/236) (red in a4) was 
observed in a subset of epidermal cells scattered throughout the epidermis, and in the stratum 
granulosum. Most phospho-S6Ser(235/236) positive cells also revealed phospho-S6Ser(240) 
staining (green in a5). Overlays are shown in a3 and a6. Double staining of CD45 (green in 
b1 and b2) and phospho-S6Ser(235/236) (red in b1 and b2) showed S6 phosphorylation in 
all epidermal layers of strongly inflamed AD lesions (b1), and restricted S6 phosphorylation 
in weakly inflamed lesions (b2). Scale bars: 50µm. 
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9.1 General remarks  
Buruli ulcer (BU) is one of the 17 neglected tropical diseases (NTDs) currently listed by the 
WHO, which affect more than one billion people, mainly populations living in poverty [1]. 
All these diseases inflict a great suffering on the affected population resulting in concrete and 
substantial public health problems [2]. Since the Yamoussoukro conference in 1998 major 
research efforts and effective control interventions for BU have been undertaken in order to 
gain deeper insights into the disease and to prevent the population at risk from sufferings [3]. 
 
Indeed, in the recent years the number of publications and consequently the knowledge 
acquired on BU disease, have substantially increased. However, some aspects still remain 
unclear. Specifically major questions like the nature of the natural reservoir and mode of 
transmission are still unanswered; as well, the mechanisms leading to the different clinical 
forms and also the mode of action of mycolactone all remain to be clarified. Beside these still 
open research questions, over the years and thanks to lessons learned from the field, numerous 
aspects of BU care and management/control of the disease have been improved. However, 
even if the early case detection and an improved differential diagnosis in order to properly 
manage the patient and to administrate the right treatment have been implemented over the 
past years, they still remain to be optimized. 
 
Within the framework of this thesis, we have contribute to strengthen the BU treatment and 
research site in the Bankim Health District (HD) of Cameroon [4]. A surveillance system has 
been implemented to promote a continuous case detection and follow up of patients to 
investigate the pathway of transmission (Chapter 3) and to support a comprehensive 
epidemiological and spatial distribution analysis of the BU evolution over time in the 
described region (Chapter 4). Additionally, the remarkable case series observed over the 
years, led to the disclosure of relevant associations between BU disease and local beliefs 
(Chapter 5).   
Furthermore, we investigated the BU treatment outcome to gain deeper insights into wound 
healing (Chapter 6) and the scarring process (Chapter 7). As a comparator, we additionally 
examined other inflammatory and proliferative skin diseases (Chapter 8).  
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9.2 BU control and transmission  
In 1998, the World Health Organization (WHO) established the Global Buruli Ulcer Initiative 
to raise awareness and to coordinate the BU control and research activities [5]. In 2014 
around 2200 new cases were reported from 12 out of the 33 BU endemic countries. It has 
been noticed that since 2010 the number of new cases has been declining in countries actively 
reporting to the WHO [6]. The reasons behind this observed decline are not clear and 
hypotheses range from the lack of data collection and bad reporting systems, especially in 
remote areas, to a lack of awareness and reduced knowledge [7]. On the other hand, especially 
in African countries, this trend at least partially, may be  also due to the establishment of 
effective national BU control programs which led to a reduction of untreated cases and 
therefore also a reduction in patients with open active lesions which could be involved in the 
transmission by spreading the bacteria into the environment. In our study area, the Bankim 
Health District (HD), we observed over 5 years of activities - from 2010 till 2014 - a 
progressive decrease in suspected BU cases. At the beginning (2010) of the control activities 
an active case-search was conducted with trained teams from the Bankim hospital and the 
foundation FAIRMED carrying-out screening and sensitization campaigns targeting 
communities suspected to be at risk of BU. At the same time training for community 
volunteers has been provided to increase participation and responsibilities in the villages. 
Volunteers acted for example as interface between the patients and the treatment centers. 
Progressively with the increase of the communities’ awareness, the active case finding 
approach was converted into passive case finding, with cases coming on their own to the 
treatment centers. In late 2015 an active in depth survey was realized in the Bankim area, in 
the frame of an integrated campaign for the surveillance and control of major skin diseases 
including BU, yaws and leprosy. In this survey four suspected BU cases were identified and 
out of them one was a RT-PCR reconfirmed (personal communication J. C. Minyem and A. 
Um Boock). On the basis of these last observations which indicate a very low BU incidence in 
the area, it appears that in the Bankim HD we are experiencing a real reduction in BU cases. 
 
    The Bankim HD, in the Mapé dam region, was originally discovered as BU endemic area in 
2007. In this area, the damming of the Mapé in 1989 and the resulting formation of an 
artificial lake were regarded as possible causes for an increase in BU incidence. In 2010, in 
collaboration with the FAIRMED, a new BU research site was build up in the Bankim HD. 
After the first survey on BU realized in the area [4], a steady flow of new cases (passive case 
finding) has been seen, which indicated that the BU control measures initiated were well 
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accepted by the local people and the personnel employed. On the basis of these good initial 
results, the surveillance system was strengthened and new control approaches were 
implemented. Beside the passive case finding, the health personnel of the Bankim hospital 
started to involve and train new actors such as community health workers and traditional 
healers in BU control activities [8]. Additionally, local populations were sensitized using 
health promotion videos in schools, local markets, churches and in general in places where 
people aggregate. The effects of these strategies needed time to be seen and despite the fact 
that the impact on BU control is still under evaluation, these interventions are likely to be less 
time and money consuming then in-depth surveys. A first evaluation showed an increased 
awareness and involvement of the communities at risk, as well as an increased number of 
cases referred to treatment centers by community health workers and traditional healers 
(personal communication F. Mou and A. Um Boock). 
 
Social interventions and community participation can facilitate early BU recognition and 
referral of cases for early diagnosis and treatment which is fundamental to prevent the 
complications associated with advanced stages of the disease [6]. Patients with advanced BU 
are usually hospitalized for a longer period and have an increased need for extensive 
interventions, like surgery and skin graft [9,10]. These kind of complications can also lead to 
life-long sequelae and deformities which can impair the quality of life of the patients and 
indirectly also of their families.   
The time-delay in seeking medical care for BU patients is a relevant issue for patient 
management but also for the health care system overall [11]. Although antimicrobial 
treatment and wound care are free of costs for the patients, several other expenses arise, 
causing delay or later potentially abandonment of treatment. A number of papers have 
discussed socio-cultural aspects which can affect the early case detection and the treatment 
seeking behaviors [12–14]. Streptomycin requires daily injections which are done at the 
health center every day meaning that the patients have to travel regularly or they have to stay 
at or close to the health center when the distances to travel are too long. In some cases the 
lesions are so severe that hospitalization is required. In addition, the proportion of affected 
children between 5 and 15 years is very high (Chapter 4) and they often require the help of a 
care taker especially if they have to stay at the hospital for wound care and antibiotic 
treatment. This implies that a member of the family has to abandon the rest of the family and 
their daily work. During the stay both the caretakers and the patients have to provide their 
own meal which adds additional costs beside the travelling efforts. A concrete solution to 
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minimize the stay at the health center would be a completely oral antibiotic treatment 
replacing streptomycin with other compounds. Currently, a valid alternative with 
clarithromycin - replacing streptomycin - has been identified and the results of ongoing 
studies appear to be promising [15]. On the other hand, proper wound care which is 
fundamental for a favorable wound healing progress, can be done so far only in the health 
center itself and a solution to this problem has to be found independently of an oral treatment. 
In order to solve the above indicated problems in the Bankim HD, so called “half-way 
houses” close to the health centers were built, for patients and relatives who live far away. 
Potential costs of the modern antibiotic treatment may also drive patients to consult traditional 
healers which are generally closer to the home village and where services can be paid for with 
natural goods. Traditional healing is linked to deep beliefs and remains central to the lives of 
many African rural communities [16]. Because of this strong cultural component people 
consult, as first approach [10], often traditional healers whether or not they can afford medical 
services. In the Bankim area traditional healers appear to play a relevant role in BU care and a 
system of collaboration between them and the local health system may be a good strategy [17] 
for a better patient management. With this collaboration, patients have the support of the 
traditional healers and might be less reticent to seek medical care and the health care system 
can benefit from receiving patients with less delay. During the past two years such a 
collaborative approach with traditional healers has been established in the Bankim HD, thanks 
to the work of anthropologists actively present in the communities and even if the benefits of 
this intervention are still to be formally proved, some promising results have already shown 
(personal communication P. Awah).  
 
Beside the early case detection another relevant aspect associated with effective BU 
control is the urgent need of new diagnostic tools which are highly sensitive and specific but 
also easy to use in the field. Currently diagnosis in remote rural areas is mainly done on the 
basis of clinical signs, but because BU can be confused with many other diseases, the 
accuracy of clinical diagnosis may be limited [18,19]. Conditions such as tropical ulcers, 
venous or diabetic ulcer, yaws, tuberculosis, cutaneous leishmaniosis and also cancerous 
conditions, maybe miss-diagnosed as BU [20–22]. Additionally, less experienced health 
workers can also mistake common wounds or mycoses of the skin for BU disease. Wrongly 
diagnosed patients are unnecessarily treated with antibiotics and this has to be avoided in 
order to prevent the development of resistant mycobacteria and to avoid side effects of the 
medication itself. The reconfirmation of BU suspected cases clinically diagnosed, is essential 
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for the following reasons: to confirm that the disease is BU (1), and therefore to be able to 
determine the precise prevalence and incidence of BU in a given area (2), to confirm new foci 
(3), to appropriately manage the disease using anti-mycobacterial therapy with or without 
surgery (4) and to confirm the failure of treatment, relapse or reinfection after treatment (5) 
[19]. 
The current gold standard diagnostic method for BU, IS2404 qPCR, which has a very high 
sensitivity and specificity, requires sophisticated laboratory equipment and highly trained 
personal and it is not applicable in the field. Nevertheless the recent guidelines of WHO 
recommend that at least 70% of the suspected cases should be laboratory reconfirmed by a 
positive PCR result [6]. The proposed goal, even if extremely important, is also particularly 
challenging considering the cost of the method and the limited resources within the countries 
to perform such tests while assuring the necessary quality standards. Reference laboratories, 
which are capable of performing qPCR or other methods for the reconfirmation, such as 
cultivation and histopathology, are rare in BU endemic African countries and therefore 
samples often have to be transported to other countries for the reconfirmation, implying high 
cost and logistic issues. For instance in the Bankim HD, swab samples were transported to the 
Swiss TPH in Basel, Switzerland for laboratory reconfirmation. Over the past years during 
our activities, we considered the possibility to set up qPCR in Bankim, but the poor 
infrastructure conditions, the lack of trained personnel and also the frequent power failures 
hindered the sustainable establishment of this method in the area.  
Additionally, building up this kind of advanced infrastructure without reinforcing the local 
health facilities and even more the general diagnostic laboratory platform should be avoided. 
Currently the only laboratory method suitable for rural health facilities and so also in Bankim, 
is the direct microscopy for the presence of AFBs after Ziehl-Neelsen staining of smears from 
ulcerative lesions or fine-needle aspirations (FNA) from nodules [23,24]. This method is easy 
and rapid but has a low sensitivity and a limited specificity [19]. In order to strengthen the 
performance and consequently the reliability of the results of the direct smear examination 
with Ziehl-Neelsen staining, a new microscope was installed in Bankim and training of the lab 
personal as well as teaching material was provided to the local laboratory technicians. A 
reduction of false positive results has been noticed after this intervention, indicating that 
indeed the training of local technician as well as adequate instrumentation are very important 
for the quality of BU diagnosis in the local laboratories. In 2014, FAIRMED has promoted a 
project to improve the health conditions of the population of the Bankim HD, by constructing 
a new pavilion for diagnosis and treatment of BU at the local hospital. Therein space was 
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dedicated for the establishment of a new laboratory. In the frame of this intervention, together 
with the public health system represented by the Bankim hospital, we decided to improve the 
laboratory infrastructure with the aim not only to strengthen research capacity in BU, but also 
to help clinicians and health workers in the management of BU patients and of patients 
suffering from other infectious and non-infectious diseases. In these premises we enabled the 
laboratory to perform a basic set of hematological and biochemistry tests relevant for the 
diagnosis and the treatment of many conditions and also to monitor the BU treatment effects. 
At present, the laboratory in Bankim is the only one in which basic laboratory analyses can be 
performed within the HD. 
 
Despite the high number of research activities, BU is often considered a “mysterious 
disease” because the natural reservoir and the mode of transmission of M. ulcerans are still 
not identified. Already from studies realized during the 1970’s, the hypothesis of human-to-
human spread was considered improbable so it is generally assumed that M. ulcerans is 
acquired from environmental sources [25]. BU foci in Africa and Australia are typically 
associated with water bodies or aquatic environment, supporting the idea that proximity and 
contact with flowing or stagnant water are risk factors for BU [25–27]. Other risk factors such 
as failure to wear protective clothes, poor wound care, and agriculture activities were 
identified but definitive indications were not yet obtained [28–30]. In some endemic areas it is 
believed that, the emergence of BU cases is related to ecological and environmental 
alterations which include damming of rivers or water bodies, agriculture activities, creating 
irrigation system and modification of water sources [26,31,32]. Such changes were suspected 
to be responsible for an increase in BU incidence in the Mapé dam region, where in 1989 the 
artificial lake was created, which led to a modification of the pre-existent environment [33] 
(personal communication A. Um Book). The identification of the distribution of BU cases in a 
given area can be very useful to elucidate the pathway of transmission and the possible origin 
of the infection. During the 5 years of activities carried out in the Bankim HD described here, 
we obtained information on the exact origin of 136 BU RT-PCR positive patients through 
geo-referencing of their houses. A cluster of patients was observed in the area between the 
Mbam river and the Mapé Dam while another cluster was located in an area upstream of the 
Mbam river. For these patients farms were additionally mapped in order to gather more 
information about people’s movements. The patients in the upstream part of the Mbam river, 
all except one, had their farms close to their houses and the river while for the patients living 
in the area between the Mapé dam and the Mbam river, the farms were far away from their 
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houses and again close to the Mbam river (Chapter 4). According to these findings, it is 
tempting to speculate that the close relation and the regular contacts between the patients and 
the river are associated with BU infection but so far no definite evidences were found to 
support this speculation.  
While studies consistently associated BU with water bodies, conclusive reservoirs could not 
be established so far although M. ulcerans DNA was detected in many biological systems 
including insects, aquatic plants, biofilms, invertebrates, snails and soil [34–36]. Nevertheless, 
the presence of M. ulcerans DNA in the environment proofs only the presence of the 
mycobacteria in a given ecosystem but is not indicative of a reservoir [25]. Several studies 
suggest that M. ulcerans is unlikely to live free in the environment while it is more probable 
that it is associated with other protective organisms or bio-elements of water body ecosystems 
[37–39]. IS2404 qPCR can detect DNA in environmental samples but because there are non-
human pathogenic mycobacteria that are IS2404 positive, this make the interpretation of PCR 
results very difficult [25,40]. The successful culture of M. ulcerans from an environmental 
sample is challenging also due to the presence of many other organisms which grow faster 
and so far it was achieved only once from an aquatic water strider collected in Benin [41].  
In south-east Australia, in feces of possums high concentrations of M. ulcrans DNA were 
found and the possums themselves showed BU skin lesions suggesting their potential role as a 
reservoir [42]. In order to gain deeper insights into the transmission and the possible way of 
infection in the Bankim HD, we collected environmental and fecal samples from villages and 
farms related to BU reconfirmed patients. These samples were tested by qPCR for the 
presence of IS2404, IS2606 and KR. Out of the collected specimens, three village water 
locations and one duck fecal sample tested positive. Particularly, in one of the identified water 
sites we observed longitudinal persistence of M. ulcerans DNA in underwater detritus which 
may indicate the presence of a special micro-environment (Chapter 3). Hypotheses of the 
acquisition of the bacteria from the environment have been largely investigated and different 
possibilities, including skin trauma or bites from water bugs and mosquitos were suggested 
[43–46].  
Recently, a new approach to gain deeper insights into transmission has been identified in the 
potential association between M. ulcerans and age. The results of our longitudinal 
observations in the Bankim HD (Chapter 4) showed that very young children below the age of 
5 are underrepresented among the BU cases [4]. Data from a sero-epidemiological study, in 
which antibody titers against the 18kDa-small heath shock protein of M. ulcerans were 
determined in sera from Cameroonian and Ghanaian healthy people living in a BU endemic 
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area, suggested that children below 5 years are less exposed to M. ulcerans when compared to 
older children and adults [47]. This reduced exposure may be due to the smaller movement 
radius of younger children or the fact that usually babies and very young children are carried 
by a caregiver and therefore might be less in direct contact with the environment. Conversely, 
children around the age of 5 years start to be more independent as well as more involved in 
the family’s activities or in playful activities which can be associated with displacements from 
home and closer contact with the environment.  
Because it is likely that the increase in exposure to M. ulcerans is related to behavioral 
changes at this age, in-depth investigations of the behavior and activities of children may help 
to give deeper insights into M. ulcerans transmission. For this reason, an analysis of water 
contact and other environmental contact patterns of children aged between 2 and 10 years, can 
be a new and valid approach to capture the behavioral changes critical for the increase in 
exposure to M. ulcerans. 
 
2.3 BU treatment and monitoring of wound healing  
Until 2004, the surgical excision of M. ulcerans infected tissue including a healthy rim, often 
followed by skin grafting to facilitate the healing, was the only recommended treatment for 
BU [48,49]. However, these surgical interventions were particularly complicated due to the 
inadequate facilities in the remote rural areas and they were associated with high recurrence 
rates of up to 28% [49–51]. After first mouse studies showed promising treatment results by 
combining the two antibiotics Rifampicin and Streptomycin (RIF/STR) a pilot study on pre-
ulcerative lesions realized in Ghana proved the efficacy of the combination also in human BU 
patients [52,53]. Based on these results, the WHO released provisional guidelines for 
treatment of BU by daily administration of RIF/STR for 8 weeks [49]. The routine 
introduction of this combination therapy in the endemic countries reduced the recurrence rates 
to around 2% [15,54,55]. Despite the fact that the antibiotic treatment is highly effective, it 
has also several limitations and complications. The daily injection of streptomycin at the 
health center represents one of the major burdens for patients since it requires the daily 
presence for 8 weeks which in turn also increases the costs and is a big obstacle for the 
decentralization of the care. Streptomycin is also associated with side effects including 
ototoxicity and nephrotoxicity especially in children [56]. Moreover, a worsening of the 
wound appearance is frequently observed during antibiotic treatment and even if this is not 
due to a treatment failure but rather a strong immune response, patients hardly accept it 
[57,58]. 
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The evaluation of the efficacy of an all-oral treatment which would omit these limitations is 
currently ongoing and clarithromycin seems to be a good alternative, which Australia and 
French Guyana have already adopted as treatment for BU in combination with rifampicin 
[49,59]. Rifampicin is currently the most effective drug in BU treatment, but it is also one of 
the front line drugs used in the treatment of tuberculosis which is also highly endemic in most 
of the BU endemic countries. Because rifampicin is given for at least 6 months against 
tuberculosis, the short treatment duration for BU might foster the development of rifampicin 
resistance [48]. Therefore the identification of new or alternative drugs as well as alternative 
therapeutic approaches for BU treatment are of great relevance [60,61]. Since development of 
a drug is very expensive hope relies here primarily on the potential use of new tuberculosis 
drugs for BU. 
 
An alternative treatment for BU is the application of heat which is based on the fact that M. 
ulcerans has a low optimal growth temperature from 28-32 ºC. Based on this finding it was 
assumed that the application of a higher temperature onto the lesion might effectively kill the 
bacteria. Successful results using this rational were already reported during the seventies and 
later in 2009 when a thermotherapy trial was successfully performed by Junghanss et al. on 
six patients treated with bags filled with a phase change material (PCM) applied onto the 
lesion for up to 56 days [62,63]. On the basis of the promising results obtained, another bigger 
thermotherapy phase II trial with 53 patients was initiated in 2010 and results showed the 
efficacy of the local hyperthermia with a cure rate around 90 % [64]. Because the application 
of such PMC has only minor side effects, mainly mild blisters and skin reactions, and they 
were also used to treat, with positive outcome, unconfirmed skin lesion, this approach could 
be advantageous in rural setting where the treatment decisions are mainly taken based on 
clinical diagnosis only  [64]. 
 
Some cases of BU that do not receive any of the established treatments discussed above, 
are speculated to heal spontaneously or after the application of traditional treatment [65,66]. 
In the course of our activities a young patient of 11 years with a laboratory reconfirmed 
(qPCR) BU lesion had been identified in 2011. The family refused the standard antibiotic 
therapy in favour of a traditional approach which consisted in the daily use of only household 
remedies prepared from the bark of two trees, E. suaveolen and S. micranthus. In 2013 the 
patient was encountered again and the ulceration at the right elbow had completely healed 
without disabilities. In 2014, the patient presented with a very good scar and without any 
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signs of relapse (Chapter 5). It is known that products derived from these trees can be used to 
manage wounds in general, however we report here only a single patient and more studies are 
needed to assess the pharmacological properties of the extracts used. On the other hand it has 
been shown that the application of herbal preparations or other traditional practices can cause 
a worsening of BU lesions [67–69], therefore to seek care at the formal health system should 
always be the first choice [70].  
 
Cases of healing without standard medical treatment are likely to be rare but have been 
reported. In the presented case we speculate that plant derivatives can play a role in the 
resolution of the lesion but of course many others aspects like the immune response, the 
wound care quality or other aspects of care such as feeding or psychosocial support can all be 
important for a favourable outcome. The presented case points out two interesting aspects: the 
first is the importance of a good follow up and a close observation of patients enrolled in the 
cohort, and the second is the growing attention on alternative therapeutic approaches for the 
treatment of BU. Once a patient is registered at a treatment centre, it is of great importance for 
the public health and research purposes that he/she is carefully documented, with detailed and 
reliable information.  
During the last few years the number of publications showing the potential therapeutic 
properties of derivatives and compounds originating from plants has appreciably increased 
and indeed many drugs currently used for the treatment of different diseases are derivatives of 
plants: this is for example the case for digoxin against certain heart conditions or quinine and 
artemisinin derivatives to cure malaria [71,72]. Additionally, in traditional medicine, plants 
are commonly used to manage wounds. Studies on plants from BU endemic areas in West 
Africa belonging to the traditional medicine repertoire are ongoing and in vitro experiments 
on their anti-inflammatory and antibacterial activities, show promising results [73–76].  
 
Another relevant component of the clinical management of BU cases is the wound care 
practice. Basic principles of wound care are to maintain the wound moist and clean, to prevent 
the wound from additional trauma and to control infections [77]; these basic guidelines can be 
very helpful to reduce the time  to healing and promote good treatment outcome by limiting 
the occurrence of sequelae [78].  Despite its fundamental role, wound care has been neglected 
for a long time, probably also because it substantially contributes to the BU treatment costs. 
Unlike the costs of drugs, it is difficult to calculate how much wound care material will be 
required per patient or how much time the health staff will need to assure good wound care 
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quality. Measures to reduce costs such as the not uncommon practice of letting the patients 
wash their own bandages instead of using each time a new one, are highly problematic. In 
order to perform wound cleaning and dressing, a clean environment and dedicated rooms are 
required and health staff has to be appropriately trained not only on the medical techniques, 
but also in cleaning and the basic principles of hygiene. In recent years, WHO underlined the 
importance of this wound care to obtain a better treatment outcome and standardized 
guidelines were developed and implemented on how BU wounds, according to size or 
presence of secondary infection, should be handled [78]. In this line, since the beginning of 
our activities at the Bankim hospital the wound care practice was improved: dedicated staff 
was trained by local experts and dedicated rooms for BU wound care became available. 
Together with wound care, prevention of disability (POD) activities are required to prevent 
sequaelae, such as contractures and stiffness of joints [78]. Because BU it is often associated 
with deformities and disabilities which can affect the life of the patient in many aspects 
including restriction of social participation due to stigma, the early rehabilitation already right 
after the diagnosis should be an integral part of the case management [79,80]. The combined 
approach of antibiotic treatment, wound care and POD activities can lead to reduced stress 
and difficulties for the patient and can help the health system to save money and resources by 
having less complicated cases. 
 
While it is often stated that BU lesions are painless, patients often complain about pain 
during wound care. A recent study by Alferink et al. investigated the pain associated with the 
wound care practice and other factors associated with pain in general in BU patients. Three 
categories of pain were identified ranging from the pain which appears right before and 
during the wound care which is mostly attributed to fear, and a third category of pain 
experienced during the removal of the bandages and during the cleaning of the wound [81]. It 
is likely that secondary infections which are very common in BU lesions, especially when 
already in advanced stages, are often responsible for the pain [82]. Several photogenic species 
such as S. aureus, P. aeruginosa, S. haemolyticus and K. pneumonia were isolated from BU 
lesions showing signs of inflammation, including pain [83,84]. While secondary infections 
and inflammation may contribute to delays in wound healing [85], inflammation is also 
physiological part of the wound healing process important to remove the affecting 
microorganisms [86,87].  
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The management of the wound is a crucial step to promote the wound healing process but 
different lesions can behave differently and there are wounds which heal easily, while others 
exhibit an impaired wound healing. Such wounds are often arrested in a state of pathological 
inflammation and enter a chronic state. Wounds can persist for a very long time in this stage 
before resolving. The wound healing process itself is very complicated and it consist of  
different phases which overlap each other and involve many different elements [88]. The 
factors affecting tissue repair are still not completely elucidated and the potential involvement 
of cellular and molecular mechanisms is under investigation [86]. In general, the factors 
leading to impaired healing can be classified into local and systemic factors; the local factors 
such as edema, necrosis, infection or low oxygen directly influence the wound while the 
systemic factors act on the general health status of the patient and can be for instance age, 
stress, co-morbidities or medications [86,89]. They are not mutually exclusive but in general 
they act simultaneously contributing to the final outcome of the wound.  
Advances in cellular and molecular biology have contributed to an expanded knowledge on 
wound healing pathophysiology, followed by investigations whether biomarkers can be used 
to assess the condition of a wound and also predict its evolution. Pro-inflammatory cytokines, 
proteases and protease inhibitors seem to have the greatest potential as biomarkers in order to 
study the status of a wound [90]. Extracellular or intracellular proteins including cytokines 
and ECM proteins can also be used as histopathological markers to monitor the events during 
the healing process in tissue biopsies. 
Despite the fact that also acute wounds can be very problematic, the major focus of research 
activities, concerning wound healing, lies on chronic non healing wounds, such as diabetic or 
venous ulcers which are responsible for a high morbidity [88]. BU lesions are indeed chronic 
wounds associated with high morbidity and in the worst cases also mortality [91]. 
Considering the literature available on other chronic wounds and using the histopathological 
approach already well-established for the diagnosis and monitoring of the treatment response 
in BU, we have analyzed markers of cell activation, myofibroblast formation and matrix 
deposition in tissue biopsies from BU lesions before, during and after treatment (Chapter 6). 
We were able to identify a set of markers which are appropriate to evaluate formation of 
granulation tissue (alpha-smooth muscle positive fibroblasts), matrix deposition (pro-collagen 
1, fibronectin and tenascin C), cell activation (phosphorylated S6), hyper proliferation of the 
epidermis (cytokeratin 16) and apoptosis (cleaved caspase 3) during wound healing.  
In BU lesions, beside the wound healing delay, scarring problems such as the formation of 
keloids and hypertrophic scars caused by an over production of collagen, have been reported. 
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In order to evaluate the suitability of our biomarkers we applied part of them to hypertrophic 
scars and keloid samples from non-BU samples (Chapter 7) and noticed a persistent signalling 
via mTOR complex 1 which induces an extracellular matrix over-production. Additionally we 
used our markers to evaluate the status of skin samples obtained from patients suffering of 
chronic inflammatory diseases such as psoriasis and atopic dermatitis to verify if our markers 
are broadly applicable (Chapter 8). Considering these findings the identified markers are 
likely to be suitable to evaluate the progression of tissue repair and also to study the 
functional basis of impaired wound healing conditions.   
Other biomarkers currently under investigation are the matrix metalloproteinases (MMPs) 
which are present in the wound fluid and are considered to be good predictors for the healing 
process [92]. High levels of those proteins in wound fluids are characteristic for an ongoing 
inflammatory response which leads to a disruption of the tissue through a constant breakdown 
of extracellular matrix elements (ECMs) and the arrestment of a wound in a chronic state 
[93]. The MMP family is composed of many different metallomatrixproteinases but in regard 
to chronic wounds and their persistent healing problem, MMP-9 and MMP-2 are the key 
players [94]. Currently several techniques are available for the identification of those proteins 
in wound fluids but the commonly used method is a substrate zymography which identifies 
the presence and amount of MMPs by measuring the degradation ability of gelatin [95].  
In collaboration with the University hospital of Basel a study is currently ongoing to evaluate 
the amount of MMP-9 in the wound fluids from venous, diabetic or decubitus ulcers. This 
study aims to test the (I) efficacy of the zymography technique to detect MMP-9 in the 
described samples, (II) stability of MMP9 in wound fluid (III) to estimate the level of MMP-9 
in the different samples and to link the amount of MMP9 with the clinical outcome and (IV) 
to evaluate the suitability of this method in order to use it for the analysis of BU wound 
exudates. If MMPs are also playing a role during wound healing of BU lesions needs to be 
evaluated. 
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9.4 Conclusion 
BU disease is a major public health problem in the affected communities. Despite the fact that 
major questions such as the natural reservoir of M. ulcerans and how it is transmitted are not 
yet fully understood, many improvements have been achieved in terms of disease control. 
From the lesson learned from 5 years of BU control and research activities in the Bankim HD, 
it is clear that it is of great importance to reduce the burden of BU on the individual patient 
and communities at risk by sensitization and active involvement of communities’ members 
including the traditional healers. Efforts towards early case detection led to a decrease of 
severe cases and an earlier treatment in turn is associated with shorter healing times and a 
reduced danger to develop disabilities.  
Furthermore, to strengthen the local diagnosis capabilities and to promote a good management 
of the patients, proper wound care practice and early rehabilitation, have been recognized to 
significantly improve the good outcome of the disease assuring the best quality of life 
possible for the patients.    
   
In this thesis, in particular, aspects of BU clinical epidemiology and transmission were 
investigated: 
 
- We identified environmental contact sites of BU patients which are potentially involved in 
the transmission of the disease; M. ulcerans DNA was found in three village water sites 
and at one of these, an in depth investigation revealed a persistent presence of M. ulcerans 
DNA over more than two years suggesting that this location may represent a natural 
reservoir of the pathogen. 
 
- In depth analyses of the geographical distribution of households and farms were realized 
on PCR reconfirmed BU cases. The results of the longitudinal observations confirmed that 
BU is predominantly a pediatric disease in Africa and that the lesions occur mainly at the 
limbs without differences among sex. Furthermore, the analysis of the geographic 
distribution of cases in the district revealed an association with the Mbam river leading to 
speculations on its role in BU transmission. 
 
- Cultural and traditional aspects are deeply rooted in the Bankim HD and they are also 
linked to the treatment of BU disease, as shown in the case of a BU patient that healed 
after receiving only household remedies.  
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Additionally in this thesis, histopathological analyses monitoring the healing and scarring 
process of BU lesions were performed. Biomarkers suitable to monitor cell activation, 
myofibroblast formation and matrix deposition in tissue biopsies from BU lesions before, 
during and after treatment were identified and used to characterize tissue regeneration, not 
only in BU lesions, but more broadly also in other proliferative and inflammatory skin 
diseases. 
 
 
Overall, the results obtained from our research projects and the activities carried out by the 
national BU control program demonstrate that a combined and multidisciplinary approach can 
contribute both to a better understanding and improved control of BU disease. 
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